Effect of Postmenopausal Hormone Replacement Therapy on Heart Rate Variability by Pace, Diane Todd
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
6-1998
Effect of Postmenopausal Hormone Replacement
Therapy on Heart Rate Variability
Diane Todd Pace
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Nursing Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Pace, Diane Todd , "Effect of Postmenopausal Hormone Replacement Therapy on Heart Rate Variability" (1998). Theses and
Dissertations (ETD). Paper 188. http://dx.doi.org/10.21007/etd.cghs.1998.0235.
Effect of Postmenopausal Hormone Replacement Therapy on Heart Rate
Variability
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Nursing
Research Advisor
Kay F. Engelhardt
Committee
Raymond Ke Cheryl Stegbauer Peggy Tagg Veeser
DOI
10.21007/etd.cghs.1998.0235
Comments
Two year embargo expired June 2000
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/188
EFFECT OF POSTMENOPAUSAL
HORMONE REPLACEMENT THERAPY ON
HEART RATE VARIABILITY
A Dissertation
Presented for
The Graduate Studies Council
The University of Tennessee, Memphis
In Partial Fulfillment
Of the Requirements for the Degree
Doctor of Philosophy
From the University of Tennessee, Memphis
By
Diane Todd Pace
June, 1998
ii
Copyright © Diane Todd Pace, 1998
All rights reserved
iii
DEDICATION
Sacrifice is such a small word to describe all that my family has done for me while I
have pursued my many dreams. Without their love, support, encouragement, and
unselfishness, I could never have achieved the many accomplishments which I have
attained in my academic and professional career.
It is therefore with a grateful heart that I dedicate this dissertation to:
Jim, my husband of 25 years, who has been my best friend and most faithful encourager
when at times I thought I could not continue-Here’s to the next 25 years of loving, sharing,
and caring;
and
My beautiful daughters, Sara and Cheryl, who have balanced their needs with my
commitments-May you fulfill God’s calling in your lives as you achieve your personal,
educational, and career goals in Occupational Therapy and Law. My prayer is that God will
provide you with a family who will give you the same love and freedom which you have
given me so that you may also achieve your dreams;
and to
My wonderful parents, Mr. and Mrs. Norman Todd, who have supported me through
many years of school, many achievements, as well as disappointments-I share this
accomplishment joyfully and gratefully with you .
To all of you, I express my deepest love and appreciation for always being there to
encourage me in so many ways. I am blessed to be your wife, your mother, your daughter.
I Love You!
iv
ACKNOWLEDGMENTS
No individual can achieve their goals without the assistance and support of others.
For the many people who have knowingly or unknowingly played a role in my life as a
teacher, friend, counselor, supporter, I express my deepest appreciation. I have been
blessed by the personal commitment of my dissertation committee to helping me achieve
this academic accomplishment. To my co-chairs, Dr. Kay Engelhardt and Dr. Donna
Hathaway, I gratefully express my appreciation for their guidance during the preparation of
this dissertation and throughout my doctoral program. The high standards which they
exemplify in their roles as educators, mentors, and researchers have established a firm
foundation upon which I will base my research career. They have always been accessible,
demonstrating their commitment to students, and have truly proven themselves worthy of
the title of role model. I would also like to thank Dr. Ray Ke. His clinical perspective gave
me new insight into reproductive health, and his willingness to share of his time in helping
prepare our grants gave me the opportunity to gain new skills. I am thankful to Dr. Cheryl
Stegbauer for her critique of the conceptual model and her willingness to assist me in
achieving a scholarly document and to Dr. Peggy Veeser  for her commitment to women’s
health and insight on menopause. Other faculty who have provided direction in my
academic career and to whom I am very thankful are Drs. Carol Panicucci of University of
Tennessee, Memphis and Nancy Dayton of Union University who frequently served as
advocates and counselors. Without my “Community of Scholars” from whom I learned
much about scholarship, teamwork, and camaraderie, I would probably have found myself
floundering through this learning process. I extend my heartfelt gratitude to Mona, Jean,
Patty, Melissa, Ann, Rebecca, for prompting me with reality checks and overlooking my
naiveté (even though they did laugh).
v
A special acknowledgment is due to Elizabeth Bradshaw, Executive Director of
Memphis FamilyCare Center. Without her support and willingness to allow me flexibility
in my work schedule, I could not have attained this degree. To the staff of American Way,
my friend and colleague, Sara Cheseldine, and my physician preceptors, Drs. Anthony
Hicks,  Art Levy, and Eugene Epstein, I express my sincere appreciation. To my patients, I
am thankful for their encouragement and willingness to participate in my learning process
and to contribute to scientific knowledge.
Additionally, I acknowledge the assistance of Mike Musick, pharmaceutical
representative for Wyeth-Ayerst Laboratories, for providing the hormones for the drug
intervention, and to the corporation for providing financial support to present the results of
this dissertation at two research conferences. I appreciate the commitment of this company
toward supporting research in women’s health. Finally, it is with great appreciation that I
recognize the partial funding for this research through NIH Grant:RO1-NR03871 for the
heart rate variability monitoring and analyses and to the College of Medicine, Department of
Obstetrics and Gynecology, for completing the hormonal assays.
vi
ABSTRACT
Minimal research has addressed effects of postmenopausal hormone replacement
therapy (HRT) on heart rate variability (HRV), a measure of cardiovascular autonomic
balance and a predictor of cardiac morbidity/mortality. Using an exploratory, pre-test/post-
test design to describe HRV in postmenopausal women (PMW) before/after six weeks of
HRT, twenty-four Black (n=15) and White (n=9) women, (mean age=55±4 years), were
recruited from two primary care clinics (n=20) and one church population (n=4) in a large
urban midsouth community. Cardiovascular risk factors for the sample included chronic
illnesses of DM (n=8), HRT (n=11), both DM and HRT (n=4), smoking (n=9), non-
exercise (n=11), and obesity quantified by sample mean BMI (mean=28±7.5). Twenty-
four hour Holter monitoring and HRV analyses were done at first visit and following six
weeks of oral self-administration of PremPro™ (estrogen: 0.625 mg; medroxyprogesterone
acetate: 2.5 mg).
PMW demonstrated lower, but normal, HRV mean values than those for healthy
female controls (n=118; age=35.6±11.8 years), Mean values were within normal limits
established for the laboratory. Pai ed t-tests with significance at p£ .10 demonstrated total
group improvement for LowHertz (p=.06) and pNN50 (p=.10). HRV values improved for
PMW with selected risk factors, consistently for values of TotalHertz and HighHertz, and,
to a lesser extent, for values of  PNN50 and rMSSD. Decreases in SDNN and SDANN
were unexpected and merit further investigation.
White PMW showed no significant differences before/after HRT ; Black PMW
demonstrated significant improvement in TotalHertz (p=.01), LowHertz (p=.03),
HighHertz (p=.01), and rMSSD (p=.05. Correlational analyses of relationship for pre-
/post-test HRV values to CV risk factors demonstrated significant (p£.10) rela ionships
across HTN and years of menopause. Pre-/post-test significant differences were found for
PMW with HTN for TotalHertz (p=.08), HighHertz (p=.04), pNN50 (p=.03), and
vii
rMSSD (p=.006), and PMW  ³  9 years menopausal for TotalHertz (p=.07), LowHertz
(p=.01), pNN50 (p=.08), and SD (p=.07). Previous research findings suggested that
PMW not on estrogen have a higher sympathetic mediation of autonomic function. Blacks
and PMW < 55 years of age, following six-weeks of HRT, demonstrated a mediation in
sympathetic/parasympathetic balance in post-test values. Because the study was exploratory
with numerous analyses at p-value£ .10, findings must be interpreted with caution.
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CHAPTER I
INTRODUCTION
It is anticipated that by the year 2000 the number of women in the United States
living beyond the age of 45 will be 43.5 million (Hargrove & Eisenberg, 1995; Scharbo-
Dehaan, 1996). A naturally occurring phenomenon during this period is the onset of
menopause occurring between the ages of 40-58 with a mean age of 51. At an increasing
life expectancy of 84 years, women may expect to live thirty-three percent (33%) of their
life in this postmenopausal, hypoestrogenic period. In recent years, much scientific data on
menopause, mostly from observational, retrospective, and correlational studies, have been
published regarding the effects of estrogen deficiency and the apparent protection from
morbidity afforded by hormone replacement therapy (HRT). However, definitive answers
are still unclear as to the physiological effects of HRT (Eskin, 1994; Gambrell, 1995;
Mastrangelo, 1993; Notelovitz, 1989; Porterfield, 1997; Scharbo-Dehaan, 1996). The
Women’s Health Initiative, a longitudinal, prospective, randomized study funded through
the National Institute of Health, is currently being conducted; however, data from this
study will not be available until 2005.
Statement of Problem
Consistent and extensive data from observational studies have indicated that
decreased estrogen production is a significant risk factor for cardiovascular disease with
coronary heart disease the principal cause of death in postmenopausal women (Newman &
Sullivan, 1996; Gorodeski, 1994). A major source of information is the longitudinal
Framingham Heart Study with biennial evaluations of a population which included 2,873
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women. During the 30 year study, 574 women (20%) developed clinical coronary heart
disease with the initial presentation of the disease proving more fatal than for men (68% of
all coronary deaths compared to 49% in men). Examination of data from 1600
premenopausal women found only six who had developed coronary heart disease (Castelli,
1994; Newman & Sullivan). Referring to 1993 American Heart Association statistics,
Gorodeski noted that 39% of women compared to 31% of men experiencing an acute
myocardial infarction die within one year post event . Rosano et al. (1997) documented an
imbalance of cardiovascular autonomic control shifting toward sympathetic hyperactivity in
menopausal women. According to research results by Kleiger et al. (1987), increased
sympathetic activity may predispose an individual to ventricular fibrillation and sudden
cardiac death. Currently, estrogen as hormone replacement therapy is increasingly
recommended for the prevention and treatment of cardiovascular disease in postmenopausal
women with many studies suggesting a 31-35% reduction in cardiovascular risk (Gupta &
Rymer, 1995; Lip, Beevers, & Zarifis, 1995; Newman & Sullivan, 1995; Notelovitz,
1989). Others have criticized many of these past studies for selection bias, however, stating
that study participants at onset may have been at lower risk for developing heart disease
than the general population due to their having a more favorable life style (Barrett-Connor,
1995; Rebar, 1994).
Heart Rate Variability (HRV), defined as the cyclic changes or fluctuations of heart
periods (R-R intervals) over time, has been shown to be a good predictor of cardiovascular
morbidity and mortality (Benson, 1995; Cowan, 1995; Kleiger et al., 1987; Saul et al.,
1988; Tiller, McCraty, & Atkinson, 1996; van Ravenswaaij-Arts et al., 1993). However,
limited research is available which examines the effect hormone replacement therapy may
have on the variability of heart rate, and if this intervention may reduce the risk of
cardiovascular disease in postmenopausal women. Research by Huikuri et al (1996), and
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Rosano et al. (1997), have provided only limited data examining this problem, indicating a
need for further research.
Purpose of Study
The purpose of this study was to examine the effect that hormone replacement
therapy exerts on cardiovascular autonomic function, as determined by analysis of 24-hour
heart rate variability, in postmenopausal women. The following three specific aims will be
addressed:
1. Describe heart rate variability in postmenopausal women, ages 45-60.
2. Describe the differences in heart rate variability in postmenopausal women before
and after six weeks of hormone replacement therapy.
3. Describe heart rate variability in postmenopausal women relative to selected
cardiovascular risk factors before and after six weeks of hormone replacement
therapy.
Conceptual Framework
The conceptual framework for this study is developed around the basic construct,
menopause. Defined by the Scientific Group on Research on the Menopause in the 1990’s
of the World Health Organization (1996), natural menopause is the permanent cessation of
menstruation, a consequence of loss of ovarian follicular activity. Menopause occurs with
the final menstrual period, followed by 12 consecutive months of amenorrhea with no other
attributed pathological or physiological rationale. Because no single independent biological
marker for the event exists, menopause can only be identified retrospectively, a year or
more after the event.
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Two secondary concepts comprise the framework for this study: hormone
replacement therapy (HRT) and heart rate variability (HRV). When viewed from a
biomedical perspective, menopause is considered an endocrinopathy resulting in a
reproductive hormone deficiency (Utian, 1990). Loss of estrogen often results in a number
of physiological effects on the cardiovascular, skeletal, and urogenital systems as well as
psychological effects. Hormone replacement therapy is a pharmacological intervention used
for therapeutic replacement of hormones which are no longer at physiological levels
postmenopause (Rebar, 1994; Voda, 1993). Heart rate variability is defined as the cyclic
changes or fluctuations of heart periods (R-R intervals) around the mean heart rate over
time (Cowan, 1995). The amount of short and long term variability in heart rate provides a
measurement of autonomic nervous system (ANS) balance, delineating between
sympathetic and parasympathetic components of autonomic control. Analysis of 24-hour
measurements of heart rate variability (HRV) has been shown to be a good predictor of
physiological distress and mortality, especially for cardiovascular disease (Benson, 1995;
Cowan, 1995; Kleiger et al., 1987; Saul et al., 1988; Tiller et al., 1996; van Ravenswaaij-
Arts et al., 1993).
    Menopause   
Researchers involved in the study of menopause often polarize on their perspective
of this phenomenon as being an endocrinopathy or a developmental event occurring during
the natural aging process (Voda, 1992). Various theoretical models have been used to
describe the concept of menopause. Most scientists agree that the menopausal experience is
a complex interaction of both multi-dimensional socio-cultural/psychological factors and
biological factors. This primary construct will be examined under two paradigms: holistic
and mechanistic/biomedical.
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     Holistic Paradigm     . The holistic paradigm of menopause describes menopause as
intrinsically related to the whole concept of nature and existence and not as an independent,
biological entity. It is visualized in a larger system picture and is described well by
Hartshorne (1978) as, “composed not of mere matter but of psychical life; pulses of
feeling, pains, pleasures....composed also of the experiences of past personal experience,
‘memory’, and also impersonal memory which is the other portions of the past than one’s
own previous experiences” (p. 142). Social scientists, Flint and Samil (1990), using a
holistic approach for their research, found that within the context of a woman’s culture, she
learned from childhood, either consciously or unconsciously, how to react to this midlife
event.
Researchers who view and describe menopause from this theoretical perspective
vigorously argue that menopause is not a disease. They contend that it is a “natural”
occurrence during the midlife period of a woman in which she is to be an informed decision
maker regarding issues related to this normal developmental phase (Coney, 1994;
Formanek, 1990; MacPherson, 1981; MacPherson, 1995; Voda, 1993). Within this model,
menopause is viewed as more than a mechanistic linear happening in the woman’s
reproductive cycle. Menopause is, instead, a multi-varied, dynamic, interrelated change
which has different meanings and experiences for the individual woman. One feminist
author noted that women experience menopause differently, some finding the transition as
difficult and disabling and others expressing it as positive and easy (Zita, 1993). She
defined menopause as a “personal, physical, cultural, and political event, located both
inside and outside the physical boundaries of the body and inside a larger body politic” (p.
68).
Anthropologists Brown and Kerns (1985) studied the experiences of middle-aged
women across a variety of cultures and societies and attempted to develop a transcultural
definition of midlife. These researchers were not able to describe a typical menopause.
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Contrary to the negative reports often documented in industrialized cultures, menopause
often remains an unreported and unrecognized event in some nonindustrialized societies.
Their research showed that for some women this midlife event was often perceived as a
positive socio-cultural change. Through menopause, women were often freed from
cumbersome restrictions imposed upon them as younger women. The change often allowed
them to enter an era of special status and provided them recognition beyond their individual
household. Woods (1994), evaluating menopause research from different perspectives
indicated that researchers from the holistic perspective, should be challenged to develop an
integrative perspective of menopause with studies transcending traditional disciplinary
boundaries.
   Biomedical Paradigm     . Within the biomedical paradigm, the mechanistic philosophy
of science is used to explain the mid-life change known as menopause. Changes in the
endocrinology of the gonadal-hypothalmic-pituitary feedback mechanism provide a basis
for defining menopause as “endocrinopathy”, a cause and effect event occurring at one
point in reproductive time. Under this paradigm, menopause is considered an objective,
biological change resulting from a gradual physiological decline in ovarian activity (Barrett-
Connor, 1995; Eskin, 1994; Grady et al., 1992; American College of Physicians, 1992;
Scharbo-Dehaan, 1996).
Two rationales have been given for endocrinological changes occurring during
menopause. One rationale asserts that cessation of ovarian follicle development initiates the
hypothalamic-pituitary change, triggering menopause as a result of compromised ovarian
function. The alternative view suggests that depletion of the ovarian follicles is actually a
consequence of age-related changes in the central nervous system effecting the secretion of
gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and
luteinizing hormone (LH) (Wise, Kranjnak, & Kashon, 1996). Follicles no longer develop
in response to these hormones resulting in loss of negative feedback inhibition and leading
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to markedly decreased levels of sex steroids produced by the ovaries (Porterfield, 1997;
Schinfeld, 1994).
Estrogen, progesterone, and androgen are the primary sex steroids secreted by the
ovaries. Estrogen is present in three types: estradiol, estriol, estrone. Estradiol is both the
most potent and plentiful of ovarian estrogen. At the time of menopause, the serum
estradiol level drops to about one sixth the mean level for younger women. Although
ovarian production of estradiol does not cease entirely, its primary source at menopause is
peripherally from androgens. Estriol is not produced by the ovaries in appreciable amounts
except during pregnancy. Estrone, the predominant estrogen in the postmenopausal period,
is produced in adipose tissue or produced peripherally from androgens (Porterfield, 1997).
Progesterone is produced in all ovarian endocrine cells and is a precursor for
androgens and estrogens. Synthesized normally during the postovulatory phase of the
menstrual cycle, its primary function is to transform the uterine endometrium, which has
proliferated as a result of estrogenic influence, into a secretory stage. In menopause, it’s
synthesis is decreased to about one third of that in the follicular phase of younger women
with primary production in the adrenal gland. This hormonal loss has important effects on
the endometrium and the basis for adding progesterone to estrogen therapy in
postmenopausal women with intact uteri (Porterfield, 1997; Schinfeld, 1994).
During the reproductive years, androgens, such as testosterone and
androstenedione, are produced by both the adrenal glands and the ovaries. With a loss of
ovarian function in menopause, as much as 50% of androgen production may be lost.
Although linked to changes in sexual behavior and attitudes of women, research has not
identified the exact influence of androgenic hormones on a woman’s libido (Porterfield,
1997; Schinfeld, 1994; Voda, 1993).
Symptoms, such as hot flashes, night sweats, mood changes, dyspareunia, vaginal
atrophy, and headaches are often described as commonplace during this period and are
8
attributed to hormone deficiencies. It is these symptoms which most often prompt some
women to seek medical intervention.
   A Conceptual Model of Menopause   . Figure 1 presents a model suggesting the
relationships and interactions of various influences on the conceptualization of the
construct, menopause. External environmental forces such as family, culture, politics,
media, education, and economy, as well as the healthcare provider, help to shape each
woman’s personal beliefs and values associated with the concept of menopause. The
openness of the circles suggests that these influences are also shaped and changed by the
individual woman once she has conceptualized a concrete image of this phenomenon. The
smaller circle represents the healthcare provider within the global perspective of the total
environment and provides recognition that this particular influence may be a strong,
independent force. Not all cultures, nor all women, will have interaction within this
influence; however, this professional often exerts a dominant effect in western cultures.
Therefore, healthcare providers have an important obligation to provide unbiased
information on menopause, specifically when the conceptualization includes decision
making regarding the use of hormone replacement therapy (Rothert, 1990). Two smaller
intertwining circles represent the biomedical and holistic philosophical paradigms of
menopause. These two major paradigms offer underlying assumptions and information
about menopause and serve as filters through which this information is assimilated into a
personal conceptualization of menopause. A small area of balance between the two
paradigms is represented by overlapping of the circles to illustrate personal resolution of
conflicting assumptions and information which have been filtered through the biomedical
and holistic paradigms of menopause. The concept, menopause, is represented by a
parallelogram which signifies the choices an individual woman makes in the development
of her personal conceptualization of the phenomenon in view of the broad influences in the
model.
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MENOPAUSE
BioMedical
Paradigm
Holistic
Paradigm
HealthCare Provider
HealthCare Provider
   Figure 1  . A Model Depictiing the Influences on the Conceptualization of Menopause.
10
   Current Research Study: A Biomedical Paradigm    . Although recognizing that
menopause is multi-dimensional, the conceptual framework for this study is developed
under the biomedical paradigm. Within this paradigm, menopause is viewed as a
reproductive hormone deficiency with women predisposed to cardiovascular disease,
osteoporosis, and other morbidity due to decreased estrogen production. Hormone
replacement therapy (HRT) is used to reduce symptomatology, prevent pathology, and
protect the woman from an accelerated aging process related to estrogen deficiency. This
study is conceptually focused on the effect this reproductive hormone deficiency has on the
cardiovascular system. From a mechanistic/biomedical perspective, it is conceptually
delineated by the effect of reproductive hormone deficiency and hormone replacement on
cardiac autonomic function (CAF). Quantification of CAF can be further described through
the measurement and analysis of heart rate variability.
     Hormone Replacement Therapy   
With loss of ovarian function resulting in a decrease in estrogen levels, proponents
of the biomedical paradigm promote the use of HRT to reduce or reverse the negative
effects caused by this deficiency. The American College of Physicians (1992) recommend
in their “Guidelines for Counseling Postmenopausal Women about Preventive Hormone
Therapy” that all women regardless of ethnicity consider taking hormone replacement
therapy as a prevention for disease and to prolong life. For postmenopausal women with
intact uteri, two regimens of therapy are suggested for clinical use: (a) estrogen (0.625 mg)
plus cyclic progestin (5-10 mg) for 10 to 14 days per month; or (b) estrogen (0.625 mg)
and continuous progestin (2.5 mg) per day.
Controversy, however, exists regarding the use of HRT with feminist researchers
and clinicians questioning results from studies on use, risks, and benefits of replacing
artificial hormones at pharmacological doses (MacPherson, 1993; Voda, 1993). Their
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belief is that transition to menopause is gradual, and menopause is a natural life changing
process, not a disease process. Under a holistic paradigm as their conceptual framework
for menopause, administration of hormone replacement therapy is illogical, unhealthy, and
unethical. The response to menopausal changes under this framework is to teach women
how to live their lives in a more healthy manner. They further advocate that information on
risks and benefits be shared with women in an unbiased manner by healthcare providers in
order to permit the women to make an informed choice on use of HRT (Logothetis, 1993;
MacPherson, 1993).
Researchers who practice under the biomedical paradigm also express some
concern about the potential side effects and risks which a woman may incur as a result of
taking HRT. Links to breast cancer have raised serious questions about the safety of HRT
even though its cardioprotective or osteoporosis prevention benefits have been lauded
(Barrett-Connor, 1995; Colditz, Hankinson, & Hunter, 1995; Ettinger, Quesenberry,
Schroeder, & Friedman, 1997). These researchers, although promoting HRT as an
intervention to improve quality of life for the postmenopausal woman, advocate that the
risks of HRT be clearly delineated and that research continue to develop alternative
approaches to therapy which would provide similar benefits (Rebar, 1994).
Both paradigms are important when examining the concept of hormone replacement
therapy. Pathological disorders (osteoporosis, cardiovascular disease) affecting
postmenopausal women have been associated with estrogen deficiency with some women
having higher risk factors for these diseases. Nonetheless, HRT is also an artificial
measure to change estrogen deficiency, and risks are apparent. The essential quality
surrounding the concept of HRT is the right of women to receive unbiased information and
to make an informed personal choice on use of HRT based on that information.
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     Heart Rate Variability   
The concept of heart rate variability (HRV) is also discussed under a biomedical
framework. HRV is the measurement of variation of one cardiac cycle to another over time
(Keehn, 1992).
    Measure of Cardiac Autonomic Balance   . Heart rate variability is defined as cyclic
changes or fluctuations of heart periods (R-R intervals) around the mean heart rate over
time. The amount of short and long term variability in heart rate provides a measurement of
autonomic nervous system (ANS) balance. The cyclic fluctuations in the ANS balance
create the variability of the heart waveforms and delineate between sympathetic and
parasympathetic components of autonomic control (Cowan, 1995; van Ravenswaaij-Arts et
al., 1993).
HRV has been utilized in scientific research to characterize the cardiac control
mechanism of the ANS (Keehn, 1992). Controlling vital functions such as cardiac action,
temperature regulation, metabolism, digestion, fluid balance, and excretion, the ANS has a
significant effect on total body homeostasis. The ANS is divided into two major divisions,
sympathetic and parasympathetic. Activation of the sympathetic division results in cardiac
responses of vasoconstriction, increased force and rate of cardiac contractility, and
increased conduction velocity in the myocardium. Aptly described by the phrase “fight or
flight”, the sympathetic nervous system prepares the body for responding to emergencies.
Exerting an antagonistic response to sympathetic function, the parasympathetic division of
the ANS induces selective vasodilation of blood vessels and decreases the rate and force of
cardiac contractility (Keehn, 1992; Spencer, Nichols, Lipkin, Henderson, & West, 1993).
   A Cyclic Phenomenon   . Continuous cycling is a positive characteristic of the
autonomic nervous system. Measurement of this cycling produces the frequency
parameters which occur in HRV. The length of time in which one cycle occurs is called a
period. Keehn (1992) relates this concept to certain mechanistic happenings: (a) the earth’s
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rotation of one day is composed of 86,400 seconds; (b) the average human breath is about
four seconds; (c) the average heart beat is 0.83 seconds; and, (d) the vibration of middle C
on a piano string is approximately 0.00379 seconds.
Keehn (1992) further discusses cyclic phenomenon as expressed in frequency, the
number of cycles which occur in a specific period of time. Named after German physicist,
Heinrich Hertz (1857-1894), a unit of frequency is called “hertz” (Hz.). One unit of
frequency is equal to one cycle per second. “With this nomenclature, the earth rotates at
0.000011574 Hz., middle C has a frequency of 264 Hz., an average heart rate is 1.2 Hz,
and respiration has an average frequency of 0.25 Hz” (p. 8).
Because the heart rate is not constant but is a composite of multiple frequency
components, HRV is characterized by discrete frequencies. Keehn (1992) further describes
the analysis of HRV by comparing it to a prism. Similar to the white light which enters a
prism and is separated into a spectrum of differentiated colors, HRV is separated by the
mathematical analysis called Fast Fourier Transformation into characteristic frequencies.
These frequencies are then used to evaluate the function of the autonomic nervous system.
   Response to Influencing Factors   . Endogenous and exogenous factors can influence
changes within the ANS leading to alteration of HRV responses. Marked variability among
individuals result from physical, psychological, environmental, or pharmaceutical effects,
as well as from variation in instrumentation or measurement of values. Various researchers
have noted the influence of age, race, and gender on variation of ANS function, with lower
autonomic function (AF) values identified in women, Blacks, and elderly (Braune, 1996;
Cowan, Pike, & Burr, 1994; Liao, 1995; Pace, Engelhardt & Hathaway, 1997). Age has
been implicated in some studies as a cause for decreasing resting heart rate variation,
suggesting a lowered vagal tone in elderly participants (van Ravenswaaij-Arts et al., 1993).
Body size and smoking status (Kageyama et al., 1997), hormone levels (Rosano, 1997),
exercise (Davy, 1996), and medications (Cowan, Pike, Burr, Cain, & Narayanan, 1993)
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have also been implicated as influencing AF. Additionally, various diseases such as
hypertension, heart failure, cardiac arrhythmias, and diabetes mellitus may also affect
results of HRV (van Ravenswaaij-Arts et al., 1993).
In addition to physiological factors, psychological factors are implicated in ANS
modulation. Mental stress evokes an increase in blood pressure and heart rate secondary to
an increase in sympathetic activity and a decrease in parasympathetic activity (Low, 1993;
Tiller et al., 1996). Research conducted by Bonnet and Arand (1997) and Chokroverty
(1993) documented diurnal changes or periodic changes during day and night periods on
HRV. Their research found autonomic alterations, primarily within the cardiovascular and
respiratory systems, during normal sleep. In non-REM sleep, a decrease in heart rate and
blood pressure was noted. Further decrease was noted during REM sleep with a
predominance of parasympathetic activity.
   Predictor of Morbidity and Mortality   . Analysis of 24 hour measurements of heart
rate variability (HRV) has been shown to be a good predictor of physiological distress and
mortality, especially for cardiovascular disease (Kleiger et al., 1987; Marquette Electronics,
1990; Saul et al., 1988; van Ravenswaaij-Arts et al., 1993). A sympathovagal imbalance in
coronary artery disease and hypertension may be detectable with HRV analysis. Low heart
rate variability has been associated with an increased risk for sudden cardiac death in
patients with diabetes and in those who have experienced a myocardial infarction.
    Measurement Indicators   . The non-invasive clinical method for assessing
measurement of HRV is conducted by 24-hour Holter monitoring which provides a
continuous recording of electrocardiographic data. Analysis of the data occurs across two
domains, frequency and time (Cowan, 1995; Marquette Electronics, 1990). Frequency
domain data are mediated by the sympathetic and parasympathetic nervous system control
and are reported by the values of Total Hertz, High Hertz, Low Hertz, and Ratio of Low to
High Hertz. Time domain data are a general measure of autonomic nervous system balance.
15
Circadian function is represented by the values of SDNN, SDANN, and SD.
Parasympathetic response by vagal influence is represented by pNN50, and rMSSD.
Individual terms are further defined in the section, Operational Definitions and in Table 1.
   Summary
According to Jacox (1974) concepts are “abstract representations of reality” (p.
351) and must be defined precisely to prevent confusion and improve communication
between researchers. The construct of menopause, and the concepts of hormone
replacement therapy and heart rate variability, have both independent meanings and, within
this study, interdependent meanings.
Menopause is visualized as the highest abstraction of the concepts. Although multi-
dimensional and influenced by many endogenous and exogenous factors, when filtered
through a biomedical paradigm, menopause is perceived as a reproductive hormone
deficiency. This deficiency affects many metabolic and physiological functions within a
woman’s body, including the cardiovascular system. Research has shown that these effects
can be altered by administering hormone replacement therapy, a pharmacological
intervention consisting of estrogen and progesterone.
The effect of HRT on the cardiovascular system has been investigated significantly
over the last decade, but little research has been done to investigate its effect on the third
concept, heart rate variability. Defined as cyclic changes or fluctuations of heart periods
around the mean heart rate over time, HRV has been used as a quantitative measurement of
cardiac autonomic balance and a predictor of cardiac morbidity and mortality. Similar to the
construct, menopause, HRV is also influenced by many exogenous and endogenous
factors. This study will investigate the relationship between the concepts of HRT and HRV
in postmenopausal women.
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Operational Definitions
1. Women who were post     menopause   were operationally defined as amenorrheic for 
12 months; FSH level ³  30 mIU/ml; serum estradiol level £  30 pg/ml (Speroff, 
1994).
2.      Hormone replacement therapy   was operationally defined as the pharmacological
replacement of estrogen (0.625 mg) and progesterone (2.5 mg). The hormones
were administered in a single, oral caplet developed and distributed by the
pharmaceutical company, Wyeth-Ayerst Laboratories as PremPro™ and dispensed
by the primary investigator, a certified Family Nurse Practitioner.
3.      Heart rate variability   was operationally defined by four frequency domain values:
Total Hertz, Low Hertz, High Hertz, and Low/High Ratio; and by 5 time domain
values: pNN50, rMSSD, SD, SDNN, and SDANN. See Table 1 for further
delineation of each variable.
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Table 1
Summary of Heart Rate Variability Measurements
Values2
Variable Definition1 Normal BorderlineAbnormal
Frequency Domain Measures
Total
Hertz
Standard deviation from all
frequencies (0.01-1.00 Hertz) over the
total test duration of 24 hours.
Represents combined sympathetic and
parasympathetic autonomic response.
³  6.11 5.95-6.10 £  5.94
Low Hertz Standard deviation from frequencies
between 0.04-0.15 Hertz.
Represents primarily sympathetic
autonomic response (including blood
pressure modulation) with influence
from parasympathetic activity.
Predominant during waking hours.
³  5.22 4.97-5.21 £  4.96
High
Hertz
Standard deviation from frequencies
between 0.15-0.40 Hertz.
Represents primarily parasympathetic
autonomic response (including
respiratory modulation).
Predominant during sleep hours.
³  3.45 3.29-3.44 £  3.28
Low/High
Ratio
Represents the relationship of low to
high frequencies over the total test
duration of 24 hours.
Provides a quantification of balance
between sympathetic and
parasympathetic activity.
Higher ratios reflect primarily
sympathetic autonomic response.
Ratios which  achieve a lower value,
close to 1.2, reflect a balance of
sympathetic and parasympathetic
activity.
1.2
(table continues)
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Table 1 (continued)
Values2
Variable Definition1 Normal BorderlineAbnorma
l
Time Domain Measures
pNN50 Proportion of all adjacent R-R
intervals varying by more than 50
msec during the total test duration of
24 hours.
Most sensitive to high frequency
components and independent of
circadian influence. Represents vagal
mediation of heart rate and
parasympathetic activity.
³  0.6 0.4-0.5 £  0.3
rMSSD Mathematical computation of the
square root of the mean of the sum of
squares of differences between
adjacent R-R intervals.
Most sensitive to high frequency
components and independent of
circadian influence. Represents vagal
mediation of heart rate and
parasympathetic activity.
³  14 13 £  12
SD Mean of the standard deviations
computed for each 5-minute block
Sensitive to variability within the 5-
minute block and higher frequency
components. Disregards variability
which occurs over longer periods.
³  33 31-32 £  30
SDNN Standard deviation of all R-R intervals
over the total test duration of 24
hours.
Sensitive to all sources of variation .
³  85 79-84 £  78
(table continues)
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Table 1 (continued)
Values2
Variable Definition1 Normal BorderlineAbnorma
l
SDANN Standard deviation of all the means of
R-R intervals from each 5-minute block
and computed over the total test
duration of 24 hours.
Differentiates how much the heart rate
differs during each 5-minute period
from the mean heart rate over 24 hours.
Sensitive to low frequencies and
variations due to posture and activity.
³  69 66-68 £  65
1    Source:   Marquette Electronics, (1990).      Heart rate variability: Physician's Guide   .
Marquette Electronics: Milwaukee, WI. Marquette Electronics (1990).
2     Source:   Cashion, A. (1998). Twenty-four hour heart rate variability measures in healthy
controls. Unpublished raw data, University of Tennessee, Memphis.
     Note.  Sample N=158, mean age=36.2 ± 11.2, range: 18-65 years; Men=40 (25%),
Women=118 (75%); Blacks=29 (19%); Whites=121 (77%); Other=7 (4%).
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Significance of Study
With average age expectancy increasing, American women can expect to spend
greater than one-third of their lives post-menopausal in a hypoestrogenic state. Based on
the 1990 U.S. Census data, there are over 40 million women who are ³  50 years and who
have had or will soon have their last menstrual period (Scharbo-Dehaan, 1996). The effect
of this hypoestrogenic state on molecular and physiological changes in health status has
been a focus of many research studies over the last decade (Rebar, 1994). These studies
have especially shown a relationship between cardiovascular disease and decreased
estrogen production.
In studying the effect of estrogen on cardiovascular disease, many studies have
reported a positive relationship on lipid levels and a beneficial effect on glucose metabolism
(Gupta & Rymer, 1996; Lip, Beevers, & Zarifis, 1995), improved endothelial function
through its antioxidant activity (Koh et al., 1997), and improved hemodynamics (Lip et al.,
1995; Rebar, 1994). Morbidity and mortality statistics published in the United States and
Great Britain have shown that in women above 50 “the cumulative absolute risk of dying
from cardiovascular disease is 31%” (Gupta & Rymer, 1996, p. 119). In an analysis of
studies on estrogen and the risk of heart disease, Rebar found significant evidence which
strongly supported the view that postmenopausal estrogen therapy substantially reduced the
risk of coronary heart disease. At the 10 year followup of the prospective Nurses’ Health
Study, researchers concluded that estrogen use was associated with a significant (up to
50%) reduction in coronary heart disease morbidity and mortality (Stampfer & Golditz,
1991).
 In a review of literature, two studies were found which examined the effect of
estrogen on HRV. Huikuri et al. (1996) and Rosano et al. (1997) both found higher heart
rate variability values in postmenopausal women on HRT. Empirical evidence has shown
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that estrogen positively affected the cardiovascular system, and measurement of heart rate
variability was considered to be a good predictor of cardiovascular status. Therefore the
significance of this study was to add further empirical data to the limited body of scientific
knowledge regarding the effect of hormone replacement therapy on HRV.
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CHAPTER II
REVIEW OF RELATED LITERATURE
Menopause is a universal phenomenon in the reproductive/developmental life cycle
of a women. As previously discussed under the conceptual framework, there are socio-
cultural/psychological changes which influence a woman’s transition to this period of life
and physiological changes which occur as a result of declining ovarian function and aging.
This study examines only the physiological change in the cardiovascular system as
measured by heart rate variability and variations in HRV which occur in response to
postmenopausal hormone replacement therapy.
Because this study was conducted within a conceptual framework of a biomedical
paradigm, the review of literature will address the research relevant to scientific knowledge
produced under this same paradigm. Additionally, the two concepts of hormone
replacement therapy and heart rate variability have been incorporated within the same frame
of reference.
Menopause
Under the biomedical paradigm, menopause is defined as a state of reproductive
hormone deficiency. It is characterized as a period of biological and chemical changes
which occur in response to the normal aging process.
   Reproductive Hormone Deficiency   
Scientists studying the physiological changes in the postmenopause period which
result in decrease of reproductive hormones, have categorized menopause as an
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endocrinopathy (Utian, 1990). Morphologic changes identified in postmortem studies,
such as a decrease in the number of ovarian follicles, occur as genetically pre-programmed
events. Additionally, examination found ovaries to be fibrotic and, occasionally,
hyperplastic and hypertrophic (Krouse, 1994; Utian, 1990).
Manifestations of the decrease in ovarian response during menopause include a
shortening of the follicular phase, cessation of ovulation, and ultimate amenorrhea.
Estrogen production changes from the primary form of estradiol-17ß produced
premenopausally to estrone, a weaker estrogen formed from peripheral conversion of
estradiol or androstenedione and also produced primarily in the adipose tissue. Whereas
premenopausal women will produce 50-500 micrograms of estradiol daily during the first
half of a menstrual cycle, production of less than 30 pg/ml documents menopausal status.
Only 15-100 micrograms of the naturally produced estrogen, estrone, are produced daily
by postmenopausal women. Follicle stimulating hormone (FSH) produced by the pituitary
gland and important in the negative feedback mechanism of ovulatory control
premenopausally, increases and remains at high level (> 30 IU/L) in menopause because
the ovary no longer responds to its stimulatory efforts. Additionally, receptor tissues in
other target organs are affected by the postmenopausal change in hormones. Physiological
changes created by the decreased estrogen also impact the skeletal, urogenital,
integumentary, neurological, and, cardiovascular systems (Krouse, 1994; Porterfield,
1997; Speroff, Glass, & Kase, 1994; Utian, 1990).
A study by Burger et al. (1995) investigated hormone changes in 380 women with
a mean age of 49.4 years (range: 45.6-56.9). Participants were divided into five groups
based upon their reporting of menstrual cycling : (a) regular cycles (Group 1-27%), (b)
change in menstrual flow without a change in frequency (Group 2-23%), (c) change in
frequency without a change in flow (Group 3-9%), (d) changes in both frequency and flow
of menses (Group 4-28%), and (e) at least three months post last menstrual period (Group
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5-13%). Data demonstrated significant increases in serum FSH across groups. Compared
to Group 1, FSH levels in Group 4 were 53% higher (p= 0.0005) and Group 5 were 253%
higher (0.0001). Significant decreases in estradiol were also noted between Group 1 and
Groups 4 and 5 (p= 0.005 and 0.0001, respectively).  Additionally, women in Group 5
who had no menstrual cycle during the subsequent year demonstrated significantly
(p=0.05) higher FSH and lower estradiol levels than did women in that group who
experienced at least one further menstrual cycle during that year. The researchers concluded
that these major hormonal changes were associated cross-sectionally with menopausal
transition and, subsequently, menopause.
   Physiological Impact of Reproductive Hormone Deficiency  
Most symptomatology which occurs during menopause has been directly related to
a decrease in estrogen. The negative impact that this decrease has on the physiological
function of the  skeletal, urogenital, integumentary, neurological, and cardiovascular
systems have been investigated by numerous researchers (Rebar, 1994).
Beyond age 40, bone reabsorption begins to exceed the formation of new bone,
accelerating after menopause and in some cases leading to bone fractures from
osteoporosis. Postmenopausal women within 10 years of the last menstrual period lose
bone mineral density (BMD) more rapidly than what can be justified only by the aging
process (Speroff, Glass, and Kase, 1994). The Postmenopausal Estrogen/Progestin
Interventions (PEPI) trial documented that osteoporosis  in the hip and spine was prevalent
in approximately 20% of postmenopausal Caucasian women after age 50 (Trial, 1996).
Researchers at the National Osteoporosis Foundation concluded that a minimum of 90% of
all hip and spine fractures among elderly white women should be attributed to the disease.
Further study has demonstrated the value of estrogen therapy in preventing bone mineral
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loss which ultimately increases the risk of fractures (Ettinger, 1994; Melton et al., 1997;
Richelson, Wahner, Melton, & Riggs, 1984).
Often primary symptoms prompting women to seek medical intervention are
complaints of flushing and diaphoresis which frequently occur at night and often lead to
insomnia. Kronenberg (1990), following a review of literature on hot flashes in
menopausal women,  reported the prevalence of this symptom was highest in the first two
years postmenopause and decreased in intensity and frequency in subsequent years. Her
research further documented thermoregulatory and cardiovascular changes during a hot
flash  and suggested that estrogen and progesterone play a role in these changes.
Genitourinary atrophy in menopause causes many uncomfortable symptoms for
women including urethritis with dysuria, urgency incontinence, vaginal drying and
pruritus, and dyspareunia (Rebar, 1994). Rebar describes the rationale for these symptoms
as related to the anatomic changes in genitourinary tract: decreasing size of uterus and
adnexa; flattening and shrinking of the labia majora  and decreasing size of clitoris; a
smaller introitus resulting from loss of subcutaneous fat and elastic tissue in the vulva; and
decreasing secretion by the Bartholin glands, shortening and narrowing of vagina, and
thinning of the vaginal mucosa which contribute to vaginal dryness, pruritus, and, in some
cases, dyspareunia; finally, an increase in the occurrence of vaginal trauma, irritation, and
infection occur with changing glycogen content and acidity of secretions from the vaginal
epithelium (p. 450).
Researchers Stenberg, Heimer, and Ulmsten (1995) noted that studies investigating
the prevalence of urogenital symptoms in postmenopausal women have been rare. While
attributing urogenital symptoms to estrogen deficiency, they concluded that these
symptoms have been difficult to investigate due to the complexity of the problems.
However, because symptoms were relieved by the administration of estrogen therapy, they
concurred that a hormonal deficit was implicated as the basis for the symptoms.
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Psychophysiologic  complaints, such as fatigue, nervousness, headaches,
depression, irritability, and dizziness, may be reported but vary across populations.
Researchers also vary as to their belief that these complaints are estrogen-related
phenomena (Speroff et al., 1994).
In recent years new research has suggested a possible link between estrogen
deficiency and Alzheimer’s disease in women. Paganini-Hill and Henderson (1994)
conducted a secondary analysis using a case-control methodology with the Leisure World
Cohort, a prospective, longitudinal study with 8,877 female residents of a retirement
community in southern California. From a cohort of 2,529 females who died between 1981
and 1992, 138 women had been diagnosed with Alzheimer’s or other dementia illnesses
likely to represent Alzheimer’s disease. Researchers determined that the risk of the disease
was less in estrogen users when compared to nonusers (odds ratio=0.69, 95% confidence
interval 0.46-1.03). The researchers concluded that the increased incidence of Alzheimer’s
disease in older women may be due to estrogen deficiency.
Findings of the Baltimore Longitudinal Study of Aging reported by Kawas et al.
(1997) added additional support to research findings documenting a protective influence of
estrogen on reducing the risk of Alzheimer’s disease. This prospective multidisciplinary
study conducted by the National Institute on Aging followed 472 peri and postmenopausal
women up to 16 years. After adjusting for education, estrogen replacement therapy (ERT)
users were found to have a lower relative risk than non-ERT users for developing
Alzheimer’s disease (0.46, 95% confidence interval, 0.209-0.997).
Finally, a recent study also indicated that estrogen may have a role in prevention of
colon cancer. Researchers in the Cancer Prevention Study II, a prospective mortality study
of approximately 1.2 million Americans begun in 1982, examined a cohort of 422,373
postmenopausal women who were cancer-free at the onset of the study. Reported by Calle,
Miracle-McMahill, Thun, and Heath (1995), in the 897 colon cancer deaths which were
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documented during the study period, the use of estrogen replacement therapy was
associated with a significantly decreased risk of fatal colon cancer.
   Cardiovascular Risk Factors
According to statistics published by the American Heart Association (AHA, 1997),
myocardial infarction (MI) is the single largest cause of mortality in American women. In
1993 in the U. S., 500,387 women died from cardiovascular disease compared to 457,211
men. Citing various studies, the AHA has alerted women of their increased risk of MI after
menopause and of the cardioprotective effect of estrogen and progesterone. The AHA has
identified the following risk factors for coronary heart disease:
1. Non-modifiable risk factors:
a. Heredity: African-Americans or individuals with a family history of 
a first degree relative with cardiovascular disease have greater risk.
b. Male gender.
c. Increasing age: Four out of five individuals dying from myocardial
infarction are over 65 years of age. Women who have an MI at these
ages are twice as often as men to die within a few weeks of the
attack.
2. Modifiable risk factors:
a. Cigarette smoking: The risk of MI is more than twice in a smoker in
comparison to a nonsmoker, and smokers are more likely to
experience a fatal MI. If combined with a family history of heart
disease, smoking greatly increases the risk. Women who quit
smoking reduce their risk after 2-3 years cessation to a risk
comparative to that of a nonsmoker.
b. High blood cholesterol levels.
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c. Hypertension.
d. Physical activity: Participation in even modest levels of low-intensity
activity is beneficial if done regularly and long term.
3. Other contributing factors
a. Diabetes Mellitus: According to AHA statistics, greater than 80% of 
individuals with diabetes die of some form of cardiovascular 
disease.
b. Obesity: Although not an independent risk factor for cardiovascular 
disease, obesity is associated with other risk factors such as 
hypertension, dyslipidemia, and diabetes.
c. Stress: Studies have suggested that a relationship exists between
cardiovascular disease and an individual’s life stress and
socioeconomic status. This factor may contribute to other risk
factors such as smoking, obesity, and hypertension.
  Impact of Reproductive Hormone Deficiency on Cardiovascular Disease   
The cardiovascular system is significantly impacted by menopausal estrogen
deficiency (Gupta & Rymer, 1996). Cardiovascular disease primarily results from
atherosclerosis in major vessels. Research has shown that prior to menopause higher high-
density lipoprotein (HDL) levels and lower cholesterol levels are present. After menopause,
however, atherogenic lipids increase, with an associated increase in atherosclerotic effects
in arteries and increased risk for cardiovascular disease (Barrett-Connor, 1995; Gupta &
Rymer, 1996; Rebar, 1994).  Reported by Nabulsi et al. (1993), the Atherosclerosis Risk
in Communities Study followed 4,958 postmenopausal women, classifying them into four
groups: (a) current users of unopposed estrogen replacement, (b) current users of estrogen
and progesterone replacement, (c) current nonusers who had previously been on some type
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of hormone replacement, and (d) current nonusers with no past history of hormone
replacement use. Results demonstrated that current users, in comparison to both
classifications of nonusers, had higher mean levels of HDL and lower mean levels of LDL
but higher triglyceride levels. Lower fasting serum glucose levels were also documented.
Loss of estrogen affects vessel endothelium and vasodilating and antiplatelet
aggregation factors which then predispose the postmenopausal woman to negative
cardiovascular outcomes (Rosselli, Imthurn, Keller, Jackson, & Dubey, 1995). In an
animal study, Wellman, Bonev, Nelson, and Brayden (1996), examined gender differences
in coronary arteries from rats. Results demonstrated pressure-induced arterial
vasoconstriction was greater in estrogen-deficient male or ovariectomized rats when
compared with similar arteries of female ovariectomized rats receiving physiological levels
of estrogen replacement. Researchers concluded that physiological levels of estradiol
increased the diameter of pressurized coronary arteries and could be a reason for the
cardioprotective effect of estrogen in women.
Further studies in peri and postmenopausal women have suggested that estrogen is
active both in vascular smooth muscle and endothelium, and its effect on hemodynamic
characteristics can be mediated by the vasoregulatory hormone, nitric oxide (Ramsay,
Johnson, Leone, & Steer, 1995; Rozenberg, Liebens, Vandromme, Hotimsky, &
Rijsselberge, 1994; Sudhir, Jennings, Funder, & Komesaroff, 1996). Nitric oxide is a
substance secreted by vessel endothelium, a monolayer of cells lining the intimal surface of
the circulatory system which aids in the moderation of coronary tone (Collins & Beale,
1996). Studies have found that oxidized lipids inhibit nitric oxide (NO), whereas estrogen
is a potent antioxidant of lipids. The cardioprotective effect of estrogen, therefore, may be
related to enhanced NO production which results in relaxation of the vessel and slows the
development of atheroma.
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Hormone Replacement Therapy
Despite increasing amount of scientific data published about its benefits and risks,
many questions about HRT remain unanswered, creating a degree of uncertainty in the
general population. Most studies until recently have been observational, retrospective, or
correlational. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI), a
prospective, 3-year clinical trial, corroborated previous studies documenting the
cardioprotective effect of HRT through its reduction of lipids (Trial, 1996).
     History   
Since the 1930s, oral estrogen has been prescribed to treat the symptoms of
menopause. In the 1970s, estrogen was one of the top five prescriptions sold in the United
States. However in the mid 1970s, several epidemiological studies reported a relationship
between estrogen use and endometrial hyperplasia and cancer with 2,900 deaths from the
disease reported in 1984. Use of estrogen therapy decreased by 40%. Following a
reexamination of the side effects, hormone replacement therapy was introduced in the
1980s with a progesterone added to the former unopposed estrogen to prevent endometrial
hyperplasia. This alteration was accepted by healthcare providers and recommended by the
American College of Obstetrics and Gynecology (Voda, 1993).
   Pharmacology
Hormone replacement therapy can be administered through a variety of
pharmacological preparations, non-oral and oral. Non-oral routes of administration such as
transdermal patches, transvaginal gels and rings, subcutaneous pellets and intranasal
sprays, and non-traditional alternatives for estrogen such as the phytoestrogens in soy
products currently exist. The most common and most frequently prescribed preparation is
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estrogen extracted from the urine of pregnant mares. Complex pharmacokinetics of
conjugated equine estrogen (CEE) are a result of various estrogenic components of the
drug. All oral preparations are converted by the body to estrone sulfate and rapidly
metabolized in the liver (Scharbo-Dehaan, 1996).
Current clinical practice guidelines dictate that postmenopausal women with intact
uteri be prescribed HRT consisting of estrogen with the addition of a progestin to prevent
endometrial hyperplasia (American College of Physicians, 1992; Barrett-Connor, 1995).
Research has provided conflicting results regarding the physiological effect of
progesterone. Grady et al. (1992) and Notelovitz (1989) reported on studies indicating that
progesterone may neutralize the positive effect of estrogen. However, in a randomized,
crossover study by Koh et al (1997), no diminished effect on fibrinolysis or lipoprotein in
postmenopausal women was observed. Additionally, research published by Barrett-
Connor, Wingard, and Criqui (1989) showed no significant differences in lipid levels for
users of estrogen only, compared to users of both estrogen and progesterone.
The American College of Physicians (1992) recommended one of two drug
administration regimens: continuous or cyclic. With a continuous regimen, the usual
prescribed dose is estrogen 0.625 mg and medroxyprogesterone acetate (MPA) 2.5 mg.
The cyclic regimen consists of daily estrogen (0.625 mg) and adding a progestin, usually
MPA 5-10 mg, for the last 12 to 14 days of the month.
No single protocol exists for the administration of HRT, nor one ideal regimen that
satisfies all women. The ideal dose is one which provides the lowest dose of estrogen and
effectively treats reported symptoms of menopause as well as reduces the potential for
morbidity/mortality which has been linked to estrogen deficit.
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     HRT Use and Compliance
Voda (1993) reported that fewer than 20% of postmenopausal women in the United
States use HRT. Additionally, women who chose to initiate therapy remained on the drugs
an average length of only 9 months. Utian and Schiff (1994) reported results of a survey
sponsored by the North America Menopause Society (NAMS) and conducted by The
Gallup Organization to: (a) explore women’s knowledge about menopause; (b) identify
obstacles which occur in the patient/physician communication regarding menopause; and,
(c) identify issues of concern to women over age 45. Using a proportionate, stratified
random digit telephone sample drawn from telephone exchanges serving the continental
U.S., 833 interviews were conducted with women between the ages of 45-60 between
May and June, 1993. Of the total sample, 53.5% were premenopausal and 43.2% were
postmenopausal. Only 27 (3.3%) were listed as unknown status. Three hundred and
twelve women (37.5%) had previously undergone hysterectomy. Caucasians comprised
86.4% and blacks, 10.2% of the total sample. The majority of the women (63%) had no
college education. When questioned about HRT, approximately three in five (58%) of the
women responded that they had never taken HRT. Only 34% were currently taking
hormones and 8% reported previous use of HRT. Women who had received a
hysterectomy were more likely to currently use HRT (53% compared to 21%). The
rationale most often given (34%) by previous users for discontinuing use of HRT was due
to drug side effects (Utian & Schiff, 1994).
Faulkner, Hutchins, and McCollam (1997) conducted a retrospective study of HRT
compliance from a large prescription claims database in Arizona. The study followed for
one year, 79,956 women, ages 40-59, who had been newly prescribed HRT. Preliminary
results demonstrated that only 46% of the patients were compliant with HRT therapy at the
end of one year.
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   Benefits of HRT
Research examining the pharmacological benefits of HRT to counter the effects of
cardiovascular disease, osteoporosis, urogenital changes, vasomotor flushing, cognition,
and colon cancer have been fully discussed under the earlier section, reproductive hormone
deficiency. A short synopsis of those benefits is reviewed in this segment.
In a manuscript reviewing the literature on hormone replacement therapy, Rebar
(1994) reported on multiple studies which have demonstrated the benefits of HRT.
Research has shown that HRT has a cardioprotective function by regulating plasma
lipoprotein levels causing a decrease in LDL and increase in HDL. Improved blood flow to
tissue, including the myocardium, increased coronary vasodilatation through mediation of
the endothelial-derived relaxing factor of nitric oxide, and modulation of local vascular wall
fibrinolytic activity which reduces the development of atherogenesis, also have important
implications from the use of HRT for the prevention and treatment of cardiovascular
disease.
Rebar also reported on studies which found that use of HRT prevented and treated
osteoporosis in postmenopausal women. Researchers at the National Osteoporosis
Foundation concluded that use of HRT ultimately reduced the risk of fractures by
preventing bone mineral loss which occured in postmenopausal, estrogen-deficient women
(Melton et al., 1997).
Symptoms caused by postmenopausal changes in the genitourinary tract have also
been eliminated or decreased following use of HRT. Urethritis with dysuria, urgency
incontinence, vaginal drying, pruritus, and dyspareunia resulting from postmenopausal
anatomic changes have been relieved by treating the estrogen deficiency. Additionally,
vasomotor complaints of flushing, hot flashes, and diaphoresis have been eliminated by
administration of exogenous estrogen (Rebar, 1994).
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Although acknowledging that research investigating the effect of HRT on mood and
psychological function have been few and poorly controlled, Rebar suggested that HRT
has a positive effect on cognition, emotions, and behavior. A case-control study within the
Leisure World Cohort by Paganini-Hill and Henderson (1994), and research by Kawas et
al. (1997), suggested that HRT may be useful for preventing or delaying the onset of
dementia caused by Alzheimer’s disease. A recent study by Calle et al. (1995) also has
shown a link between HRT and a reduced risk of colon cancer.
     HRT and Breast Cancer  
Evidence suggesting that estrogen use increases the risk of breast cancer is a
continuing source of concern for postmenopausal women, although conflicting data exist
on the actuality of this risk. A meta-analysis of studies investigating a link between
postmenopausal estrogen therapy and risk of breast cancer found no overall increase with
short term hormone use (Steinberg, Thacker, & Smith, 1995). In contrast, two other meta-
analysis of studies on long-term estrogen use found that breast cancer risk increased with
duration of estrogen use, with a 25-30% increase after ten years or longer of sustained
therapy (Grady & Ernster, 1991; Steinberg, Smith, Thacker, & Strough, 1994). Ettinger,
Quesenberry, Schroeder, and Friedman (1997) also found a link between breast cancer and
long-term estrogen use. From a longitudinal study of 454 women who were followed an
average of 31.1 years after menopause, 232 women had taken estrogen for 17.2 of those
years. At the conclusion of the study, 72% of the estrogen users and 57% of nonusers
were still participating in the study. The researchers found a twofold risk of breast cancer
with long-term use of estrogen.
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Heart Rate Variability
Heart rate variability is defined as the cyclic change or fluctuation of heart periods
(R-R intervals) around the mean heart rate over time. The amount of short and long term
variability in heart rate provides a measurement of autonomic nervous system (ANS)
balance, delineating between sympathetic and parasympathetic components of autonomic
control . The non-invasive clinical method for assessing measurement of HRV is by 24
hour Holter monitoring which provides a continuous recording of electrocardiographic
data. Analysis of the data occurs across two domains, frequency and time. Frequency
domain data are mediated by the sympathetic and parasympathetic nervous system control
and are reported by the values of Total Hertz, High Hertz, Low Hertz, and Ratio of Low to
High Hertz. Time domain data are a general measure of autonomic nervous system balance
and reported by the values of pNN50, rMSSD, SD, SDNN, and SDANN (See Table 1)
(Cowan, 1995; Keehn, 1992).
   Clinical Applications   
Measurements of 24-hour heart rate variability (HRV) have been shown to be good
predictors of physiological stress and mortality, especially for cardiovascular disease.
Sympathovagal imbalance in coronary artery disease and hypertension may be detectable,
and low heart rate variability has been associated with an increased risk for sudden cardiac
death in patients with diabetes and in those who have experienced a myocardial infarction.
Kleiger, Miller, Bigger, and Moss (1987) were among the early researchers to
report on clinical applications of HRV. They investigated HRV as a predictor of long term
survival following an acute myocardial infarction (MI). In a multi-center study of patients
from nine hospitals located in five U.S. cities, 808 patients younger than 70 years old who
had survived the acute phase of MI were enrolled in the study. One HRV variable,
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identified as the 24-hr SD by Kleiger, was defined as the standard deviation of RR intervals
around the average This value is now labeled SDNN (Keehn, 1992). Participants were
divided into three groups by their SDNN value: (a) < 50 (n=125), (b) 50-100 (n=472), and
(c) >100 (n=211). Results indicated that participants whose SDNN values were less than
50 ms had approximately a four-fold increased risk of dying during follow-up when
compared with participants whose SDNN value was more than 100 ms.
Saul et al. (1988) conducted a study to evaluate the differences in cardiac autonomic
balance in 21 normal control participants and 25 participants with chronic stable congestive
heart failure (CHF). HRV results corroborated other studies demonstrating a diminished
vagal response and a preserved sympathetic modulation of heart rate in participants with
CHF. Additionally, these results were not influenced by age as was noted in HRV values
in normal controls.
Decreased HRV, specifically in values measuring parasympathetic modulation, has
been documented in individuals following sudden cardiac arrest (Cowan, 1995; Magid et
al., 1987; Martin et al., 1987). Cardiac arrest is caused by electrical instability, primarily
augmented by sympathetic hyperactivity. Following an arrest, it has been hypothesized that
loss of parasympathetic tone allows for this uncontrolled sympathetic hyperactivity
increasing the risk for event mortality. These studies indicate that analysis of HRV may
identify patients at higher risk for sudden cardiac death.
The association of decreased HRV with an increased risk for new cardiac events
was studied in a sample of 2501 participants, mean age of 53 years with no clinically
apparent signs of cardiovascular disease, in the Framingham heart study. During a mean
follow-up of 3.5 years, 58 individuals experienced a cardiac event. Adjustment for age,
sex, cigarette smoking, diabetes, left ventricular hypertrophy, and other relevant risk
factors was made in the analysis of data. Results showed all HRV measurements with the
exception of the Low/High ratio were significantly associated with risk for a cardiac event
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(p=0.0016). Findings suggested that HRV analysis could offer healthcare providers
valuable prognostic data on cardiovascular disease (Tsuji et al., 1996a).
Recent research has also indicated that HRV analysis may be used to further define
psychologically based illnesses such as depression and anxiety by evaluating the
sympathovagal balance. Tiller, McCraty, and Atkinson (1996) conducted a study with 20
individuals trained in the Freeze-Frame bio-feedback type technique where they were taught
to recognize stressful feelings and initiate interventions to regain emotional/physical
balance. Participants were monitored for 24 hours during a normal business day in their
workplace and instructed to use the Freeze-Frame technique on at least three occasions
when they were sensing stress or feeling out of balance. During positive emotional states, a
marked increase in values representing parasympathetic mediation was noted.
  Influences on HRV   
Although studies have indicated that a variety of factors may influence HRV values,
some results have been conflicting.
   Age   . Increasing age has been implicated for decreasing HRV (Liao et al., 1995;
Murata, Landigran, & Araki, 1992; Schwartz, Gibb, & Tran, 1991; Veerman, Imholz,
Wieling, Karemaker, & Montfrans, 1994). However, Reardon and Malik (1996), although
identifying a significant difference (p=<0.05) in the HRV triangular index which gives an
estimate of overall HRV measurement, reported no significant change in vagal
measurements of rMSSD with age. They evaluated HRV on 56 healthy participants
between the ages of 40 and 102 years, 39 of whom were women. None had a history of
heart disease or were taking medication which could affect cardiac autonomic function.
Parameters were compared between participants younger and older than 70 years. The
researchers concluded that the time domain short term component (rMSSD) reflecting vagal
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modulations of heart rate was not affected by age. Saul et al. (1988) has also reported that
the effect of age on HRV is not a significant factor in patients with congestive heart failure.
     Gender  . In a study to describe the effects of gender and age on HRV in healthy
participants (N=111), Cowan et al. (1994) examined 40 men (mean age= 57±15) d 71
women (mean age= 52±15). Results showed significantly lower values in healthy women
than in healthy men for all variables except the high frequency (High Hertz) and the two
time domains representing vagal modulation (rMSSD and pNN50). Another study by Pace
et al. (1997) examined gender differences in 253 participants (123 with diabetes) awaiting
renal/renal-pancreas transplantation. Researchers found lower mean HRV scores for
women although no significant difference between gender at an alpha of 0.05 was noted.
   Pharmacological Intervention   . Drug therapy may influence HRV and should be
considered when analyzing HRV results. Van Ravenswaaij-Arts et al. (1993) reported that
spectral analysis helped to quantify sympathetic and parasympathetic activities of drugs
such as beta-blockers and calcium channel blockers. In normotensive adults, fast
fluctuations in heart rate were mediated through the vagal influences of atenolol. The
researchers further reported on a study by Guzzetti and colleagues which investigated the
effect of atenolol in hypertensive patients. An increase in the parasympathetic high
frequency value (High Hertz) was observed corresponding to a decrease in the sympathetic
low frequency value (Low Hertz). Additionally, van Ravenswaaij-Arts found that calcium
channel blockers had varying responses on HRV. In postinfarction patients, Diltiazem
reduced low frequency HRV similar to those values demonstrated by the beta blockers.
Nifedipine, conversely, did not reduce sympathetic activity. Sedatives, analgesics, and
anesthetics were also found to negatively influence HRV.
Salo et al. (1996) investigated the effect of drugs on HRV. Thirteen hypertensive
diabetic participants, mean age 48 (± 4 years), were assessed during treatment with a
cardioselective beta blocker (metoprolol) and an ACE inhibitor (enalapril). Both drugs
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decreased blood pressure comparably in the sample. Metoprolol also decreased heart rate
and HRV low frequency values. Enalapril did not significantly alter HRV. Noting that
HRV was significantly abolished in participants with hypertension, diabetes, and
autonomic neuropathy, the authors suggested that an ACE inhibitor may be a better
alternative for individuals with related disorders.
   Physical Activity   . Positive effects of exercise on HRV have been demonstrated in
various studies conducted with older patients (Levy et al., 1992) and those with chronic
illness such as diabetes (Howorka et al., 1997)  and coronary artery disease (Osterhues,
Hanzel, Kochs, & Hombach, 1997). In postmenopausal women, a study by Davy,
Miniclier, Taylor, Stevenson, and Seals (1996) examined HRV in 9 physically active
women (mean age=53 ± 1 year) and 11 age-matched controls (mean age 56 ± 2 years). The
time domain variables were significantly higher in the active women (p=<0.05). Mean
frequency  values were also increased compared to those of the less active women.
   Substance Abuse   . Chronic alcoholism has been associated with autonomic
neuropathy resulting from impairment in vagal modulation of cardiac function (Omboni,
Parati, Rienzo, Wieling, & Mancia, 1996). Smoking has also been associated with lower
values of HRV (Tsuji et al., 1996b).
     HRV and Estrogen
According to Collins and Beale (1996), estrogen has beneficial effects on the
autonomic nervous system by modulating the influence of sympathetic/parasympathetic
influences. A study by Huikuri et al. (1996) used HRV to examine sex-related differences
in autonomic modulation of heart rate in randomly selected, age-matched men and women.
A sample of 186 women and 188 men, mean age 50 (± 6) y ars demonstrated gender
differences in cardiovascular autonomic regulation suggesting that the vagal responses to
cardiovascular unloading was attenuated in women. A secondary analysis of data was
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reviewed on 92 women, separated into two groups based upon estrogen use; each group
consisted of 46 women (mean age 50 ±  4 years). The researchers found that heart rate
variability was higher for postmenopausal women on estrogen replacement therapy (ERT)
compared to women without ERT and suggested that hormonal factors may influence
changes in autonomic modulation. Significant differences were noted between the two
groups of women in time domain variables of SD (p=0.01) and pNN50, a measurement of
vagal function (p=0.05). Women on estrogen also demonstrated significantly better values
for the frequency domain variables (High Hertz: p=0.05; Low Hertz: p=0.01).
A second study by Rosano et al. (1997) supported previous results that
postmenopausal women have an increased sympathetic tone which may cause an abnormal
control of the cardiovascular system. A sample of 30 women, mean age 56 (± 6) years,
nonsmokers, with no symptoms or evidence of cardiac disease underwent 24-hour
ambulatory ECG monitoring. Baseline HRV results demonstrated an imbalance in
autonomic control with primarily sympathetic hyperactivity demonstrated by low values of
high frequency (High Hertz) and a high low/high frequency ratio. Eighteen women were
subsequently placed on transdermal ERT and 12 women refused ERT, but served as
controls for the study. HRV analysis was repeated at four weeks and four months.
Significant changes (p=0.05) were noted at four weeks in the ratios reflecting
parasympathetic modulation (High Hertz, rMSSD) and sympathovagal balance observed by
a decrease in the Low/High Ratio. All values were significantly improved at the four month
retest with the high and low frequency values and pNN50 significant at p= 0.01 suggesting
that an “extra period of estrogen exposure is needed to stabilize the autonomic control of the
cardiovascular system in symptomatic menopausal women” (p. 816).
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   Related Research Studies   
A current research study by Engelhardt, Pace, Hathaway and Andersen (1997) is
examining the relationship of female sex steroids to autonomic function (AF). In seeking to
evaluate the hypothesis that the autonomic nervous system is a significant mediator of the
protective effects of estradiol on the cardiovascular system, the researchers are conducting
vasomotor and cardiac evoked testing, in addition to 24-hour heart rate variability, within
four groups of women based upon reproductive status. Preliminary results suggest that
PMW on HRT have more optimum AF levels than PMW not on HRT in some, but not all,
tests. More optimum levels were observed in the HRV time domain tests of SD, SDNN,
and SDANN. In this study, age effects on HRV have been evident.
A secondary data analysis by Pace, Engelhardt, & Hathaway (1996) examined
gender differences in autonomic function within a population of 253 patients awaiting
kidney/kidney-pancreas transplantation.  Results demonstrated that women demonstrated
poorer values which were significant/approaching significance in 6 of 16 AF variables
tested when compared to men with similar pathology. Lower, although not significant, AF
values were found by Cashion (1998) in healthy female controls when compared to healthy
male controls. Both studies suggest that estrogen may influence autonomic nervous system
function.
   Summary
A significant amount of literature, as previously reviewed, is available about
menopause addressing the effect of decreased reproductive hormones on biological
processes. Metabolic alterations occurring as a result of this deficiency impact multiple
body systems, especially the cardiovascular system. Many studies have also addressed the
effects of hormone replacement therapy in preventing morbidity and mortality resulting
from these metabolic alterations. Limited research, however, has been conducted
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investigating the effect of menopause, or the effect of postmenopausal HRT, on heart rate
variability. This study, therefore, was conducted to provide additional descriptive data on
HRV in postmenopausal women and to investigate differences in HRV across selected
cardiovascular risk factors before and after the administration of HRT.
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CHAPTER III
METHODOLOGY
Research has demonstrated that increased risk of cardiovascular disease (CVD)
exists in postmenopausal women, and hormone replacement therapy decreases cardiac risk.
Because analysis of HRV has been used to predict cardiac morbidity and mortality,
consequently this study was designed to investigate cardiovascular health of PMW using
HRV. Selected factors identified by the American Heart Association as increasing risk of
CVD were also investigated in their relation to HRV in PMW. This chapter will discuss
research aims, study design, sample and site, drug intervention protocol, instrumentation,
and procedures for a study investigating the effect of postmenopausal HRT on HRV.
Research Aims
Three specific aims were identified for conducting this study:
1. Describe heart rate variability in postmenopausal women, ages 45-60.
2. Describe the differences in heart rate variability in postmenopausal women before
and after six weeks of hormone replacement therapy.
3. Describe heart rate variability in postmenopausal women relative to selected
cardiovascular risk factors before and after six weeks of HRT.
Research Design
This research study was conducted in the Mid-South at two community-based
ambulatory care clinics and a suburban church using a therapeutic intervention, one-group
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pre-test/post-test design. An early decision was made to place minimal limitations on the
exclusion criteria for participation. Because many women in community settings, although
healthy, have variations in their lifestyle adaptation, exposure to environmental factors, and
presence of concomitant disease, the study was designed to allow women usually seen in
this population to serve as their own controls. According to Campbell and Stanley (1963),
this design effectively controls for internal validity issues. Historical events such as
seasonal and time changes, variations in physiological measurements such as temperature,
pulse, respirations, blood pressure and weight, and environmental factors such as stress,
change in diet and exercise which might influence HRV values were assumed to produce
similar effects in both the pre-test and repeated measures post-test values of the same
individual over a six-week time period.
Sample and Site
This study used a non-probability, purposive sampling to obtain representative
proportions of participants with varying ethnic and socio-economic demographic
characteristics. Following approval to conduct the research from the Institutional Review
Board at the University of Tennessee, Memphis and from the Medical Director for the
community-based clinics (see Appendix A), participants were recruited from the following
sites: (a) a community-based urban family practice clinic in the eastern geographic area of
the city, (b) a community-based inner city family practice clinic, and (c) a suburban church.
Recruitment in these settings allowed for a diverse population of participants with varying
ethnic and socio-economic demographic characteristics.
The following inclusion/exclusion criteria were established for the study:
Inclusion Criteria: 1. Women between the ages of 45 and 60 years;
2. Self-reported amenorrhea for 12 months;
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3. Hormone levels: FSH ³  30 mic/ml and Estradiol £  30 pg/ml;
4. Expressed willingness and ability to take an oral medication;
5. Expressed willingness to complete the six week study.
Exclusion Criteria:1. Past medical history of hysterectomy;
2. Undiagnosed abnormal vaginal bleeding;
3. Past medical history of breast cancer;
4. Family history of first-line relative with breast cancer;
5. Current use of hormone replacement therapy. However,
individuals on current HRT could participate following a 6-week wash-out period. Two
women in the study met this criteria.
Although not considered as inclusion/exclusion criteria, participants were
encouraged to notify their primary care provider of their participation in the study.
Additionally, because of recognized health maintenance benefits, participants were also
encouraged to have their yearly gynecological exam and mammogram if it had been one
year or longer since their last evaluation.
Twenty-nine women met study criteria with three declining to participate. Twenty-
six women who met the inclusion criteria and agreed to participate in the study were
enrolled. Twenty-four women completed the study. One of the enrolled women elected to
discontinue HRT after three weeks, secondary to medication side effects; a second woman
had no phone and was lost to follow-up.
Drug Intervention Protocol
The intervention protocol for this study was based upon the 1992 “Guidelines for
Counseling Postmenopausal Women about Preventive Hormone Therapy” published by the
American College of Physicians (1992). The HRT guidelines for women who have intact
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uteri is the administration of estrogen with the addition of a progestin. The frequently
prescribed clinical regimen of oral conjugated estrogen, 0.625 mg and
medroxyprogesterone acetate, 2.5 mg taken on a daily basis, was used as the drug
intervention for this study. Drug samples for distribution to patients through provider
offices were supplied by a pharmaceutical representative of the company. The drugs were
combined in a single peach tablet, packaged individually on a blister card marketed as
PremPro™, a trademark of Wyeth-Ayerst Laboratories. A package insert (Wyeth-Ayerst
Laboratories, 1997, January) and a consumer booklet (Wyeth-Ayerst Laboratories, 1997,
April) supplied by the company were distributed to each participant at the onset of the
study. Potential side effects were discussed with each individual The medication samples, a
44-day supply of tablets, were dispensed by the principal investigator, a certified Family
Nurse Practitioner with prescriptive authority from the Tennessee State Board of Nursing
(see Appendix B).
Instrumentation
   Demographic   
Two demographic/health history forms (see Appendix C) designed by the principal
investigator were used during the study. The General Information data form was completed
by the participant and documented demographic information including age, race, marital
status, education, and social behaviors including smoking, exercise, and alcohol
consumption. Information was also solicited on reproductive history, current and past
medical history, and family history. The Pre/Post-Test Health Form was completed by the
primary investigator at the time of enrollment and retesting. The form verified basic
demographic information, validated adherence to the inclusion/exclusion criteria, and
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allowed for documentation of physiological variables such as pulse, blood pressure,
height, and weight. In addition, the date for retesting was noted.
     Hormone Assays   
Analysis of serum estradiol and follicle stimulating hormone (FSH) values were
performed by automated chemiluminescence immunoassay using the CIBA-Corning ACS:
180 Plus SystemÒ  manufactured by Chiron/Diagnostic Corporation. Intra-assay
coefficients of variation were noted as 6.49% for estradiol and 3.56% for FSH. Inter-assay
coefficients of variation were noted as 11.1% for estradiol and 4.98% for FSH
(Chiron/Diagnostic, 1996). Automated hormonal assays were performed by licensed
medical laboratory technicians at a certified laboratory directed by the University of
Tennessee College of Medicine, Department of Obstetrics and Gynecology.
     Heart Rate Variability   
Heart Rate Variability (HRV) was measured by use of the Marquette ElectronicsÒ
Ambulatory ECG Analysis and Editing Systems, version 5.8 software program with Series
8500 Holter recording monitor (Marquette Electronics, 1990). The Holter monitoring
equipment  provides continuous recording of 24-hour non-invasive electrocardiographic
data. MarquetteÒ  HRV software analyzes beat to beat variability of heart waveforms,
providing R wave detection and offering discrimination and reproducibility.
Standard monitoring procedures provided by the Physiological Function Laboratory
and supervised by the director of the laboratory at the University of Tennessee, Memphis,
located at the W. F. Bowld Hospital were used during this study. The standardized Holter
monitor protocol (see Appendix D) developed by the laboratory research team was used to
insure consistency in testing. The PI for this study connected all participants to the Holtor
monitor to insure reliability of electrode placement. The PI was  instructed in the protocol
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and was observed in a correct return demonstration by the research technician. This
technician had received intensive training in the procedure and was currently testing
approximately 15 patients a week at the laboratory using the established protocol.  
HRV data analysis for this study was conducted only by the PI to insure reliability
of analyses. Two recordings of 24-hour electrocardiographic data were obtained on each
participant pre-intervention and post-intervention, six weeks later. Ten percent of both the
pre- and post-intervention tapes were reanalyzed by the PI to insure intra-rater reliability. 
The analysis of HRV was done by first downloading each tape into the Marquette®
software program which provided a mechanical analysis of beat morphology. The QRS
beats were divided into multiple classifications by the computer program but were manually
reviewed by the PI and reclassified, when necessary, for correct labeling of normal,
artifact, ventricular ectopy, and unclassified beats. Incorrect labeling was edited by the PI
because undetected or misclassified beats could add artificial variability, reducing internal
validity (Keehn, 1992).
 Following manual validation of beat classification, HRV analysis was performed
on each tape,  calculated by the Marquette® software (Marquette Electronics, 1990) using a
Fast Fourier Transform algorithm with the resulting expression transformed into Hertz
frequency values by an additional computerized mathematical calculation. Non-spectral
measurement of time domain components of HRV were also calculated by the Marquette®
software. Calculations of HRV values have been reported reproducible across intervals
ranging from 3 to 65 days in 14 normal participants (Kleiger et al., 1987). Quality
assurance data provided by the manufacturer stated that “calculations  and statistics of the
Marquette HRV program can be verified from laboratory measurements of predictable test
signals” (Keehn, 1992) p. 139.
Cowan (1995) reported validity of the time domain variable measurements showing
high correlations (r=.90) among the individual values. Strong correlations of the time
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domain variables with the frequency domain variables were also demonstrated. Cowan also
documented high correlations between frequency domain variables using two different
methods of HRV analysis, Fast Fourier Transform and Autoregressive (r=.97 and r=.99).
Kleiger et al (1991) reported data on reliability attesting to the reproducibility of 24-hour
HRV measurements.
Normative data and reliability and validity studies for data obtained at the UTM lab
is ongoing. Additionally, a current study by Engelhardt, Pace, Hathaway, and Anderson
(1997) is currently being conducted to determine normative values of HRV in healthy
women at varying points in their reproductive history.
Procedures
   Recruitment/Enrollment  
Letters were sent to the providers at the clinics notifying them of the study, and
posters explaining the study were posted at all three sites. Patients who reported to the
clinics during the period between September, 1997 and January, 1998 and met the study
criteria were invited to participate. Non-clinic participants were recruited by the PI through
distribution of flyers at a suburban church. Individuals who were interested in participation
were directly contacted by the PI, study details were explained, and a mutually agreed upon
date and time scheduled for testing.
Twenty-six individuals who met the inclusion and exclusion criteria were enrolled
in the study. The study protocol was explained to each participant by the PI and a signed
consent form was obtained (see Appendix E). Appropriate data was obtained on the Pre-
Test Health Form, and the self report Demographic Information Record was distributed to
the participant with verbal instructions on how to complete the form (see Appendix C).
Participants were encouraged to alert their provider of their participation in the study and to
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continue with routine health maintenance and/or follow-up visits. For any medical
questions or concerns, they were instructed to discuss those issues with their provider. For
any questions on follow-up related to the study, a phone number providing 24-hour access
to the PI was provided.
At the time of enrollment, a return appointment time was made for repeat testing on
or between days 40 and 44. Participants were reminded of and confirmation obtained by
phone one week prior to the scheduled post-test appointment.
   Blood Collection for Hormone Assays   
The procedure for venipuncture was explained to the participant, and blood was
drawn by the PI, a Family Nurse Practitioner, or a medical assistant trained and certified in
venipuncture technique. Following universal precautions, 20 ml of venous blood was
obtained in two serum separator blood collection tubes. Tubes were delivered to the on-
site, Level Two CLIA certified clinic laboratory by the PI and handled according to
established laboratory protocol by a licensed Medical Laboratory Technician. The blood
was centrifuged to separate plasma and serum. The serum was placed in a plastic blood
container tube and placed in the freezer, again following established laboratory protocol.
All specimens were batched and frozen until hormone assays were run by a certified
laboratory with the University of Tennessee, Memphis, College of Medicine (see
instrumentation). Results were documented on a lab sheet and returned to the PI.
   Drug Intervention Protocol  
An envelope with 44 individual PremPro™ tablets in blister packaging was given to
each participant, and they were instructed that more tablets were distributed than they might
have to take. All participants were informed of potential side effects of the medication, and
a drug insert information sheet and consumer brochure was distributed. To promote
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compliance with taking the daily medication, they were given a Drug Documentation
Calendar (see Appendix F) and instructed to mark with an “X” each day that the medication
was taken. Should the tablet not be taken, they were instructed to circle the day and not to
take any missed pills. The calendar was to be returned at the time of retesting. Additionally,
participants were instructed to keep a diary of any changes which might occur during the
six-week study time, such as change in prescribed medication, change in exercise level,
hospitalization, unusual stressor, and to note the change on the Drug Documentation
Calendar.
     Heart Rate Variability   
Twenty four hour ambulatory Holter monitoring was conducted on each participant
at enrollment and again on completion of the study on or between days 40 and 44. The
chest area of the participant was cleaned by vigorous rubbing of a pre-packaged alcohol
swab and then by a dry gauze pad. Five chest electrodes were placed in a modified Lead
One position (see Appendix D). Lead wires were attached to the monitor according to
manufacturer’s instructions. Both the electrodes and leads were securely taped to the
participant’s chest to prevent dislodgment. The electronic recording monitor, weighing
approximately 12 pounds, was placed in a purse-like holder with a strap allowing the
participant to wear it around their neck or waist. A one page diary (see Appendix D)
supplied by the Physiologic Function Laboratory with the monitors, was given to each
participant with instructions to note the time of meals, exercise, any unusual stressors, and
sleeping time on the diary. Additionally, the following directions were given to each
participant orally by the PI:
1. Monitoring will be continuous for the 24-hour period. Do not 
disconnect the monitor before the specified time given by the PI.
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2. Do not shower or allow the electrodes to become wet. Should the tape 
become loose on the electrodes, reapply new tape.
3. At the end of 24 hours, remove the electrodes from the chest. Do not 
disconnect any leads. Return the equipment, unopened, with the data form 
and diary, to the site at which testing was initiated.
   Summary   
Enrollment with venipuncture, Holter Monitor application, and instructions took
approximately 60 minutes. Retesting took approximately 25 minutes because no further
enrollment instructions were necessary. Participants who elected to continue HRT on
completion of the study were given a prescription for PremPro™. For individuals who had
been recruited at the clinic sites, this procedure was documented in their medical record.
For non-clinic participants, a prescription for two months was given by the PI with
instructions to contact their primary care provider for follow-up and continued drug
prescription refills. They were informed that results would be mailed to them following
completion of the study
Except for venipunctures and analysis of hormonal assays, data collection was
completed by the PI. HRV analyses and all data entry for statistical computation was also
completed by the PI.
Protection of Human Subjects
Approval to conduct the study was obtained from the Institutional Review Board of
the University of Tennessee, Memphis. Additional approval for clinic site utilization was
obtained from the executive and medical directors for the clinics (See Appendix A).
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Although a drug intervention was involved with the study, dosage was at
recommended therapeutic levels and minimal side effects were expected for the 6-week
study protocol. Heart rate variability testing by the Holter monitor was expected to cause no
discomfort other than occasional skin irritation at the site where the chest patches were
taped. Collection of blood samples were done by standardized protocol and by qualified
professionals and presented minimal risk or discomfort to participants. There were no
known legal, psychological, or social risks involved.
Subjects were fully informed of identified procedures prior to enrollment in the
study and again at retesting. Additionally, they were informed of potential risks and
benefits and signed an informed consent form. Opportunity was given to read the form or
have it read to them by the PI. Participants were assured that individual data would be kept
confidential. To insure anonymity of participants and confidentiality of data, participants
were assigned a study number and collected data was entered on a computer spreadsheet by
that number. Original data collection sheets with the matching assigned study number were
maintained in a locked security cabinet accessible only by the PI or appropriate faculty
representative. Participants were informed that if study results suggested a possible health
problem which might need immediate attention, they would be notified and asked if they
wanted that information released to their provider. They were further instructed that their
participation in the study was voluntary, and they could withdraw from the study at any
time with no repercussions, although notification of withdrawal to the PI was encouraged.
Analysis
Data were analyzed using JMP® Statistical Discovery Software (SAS Institute,
1995). Classification and summarization of sample demographics were calculated through
use of descriptive statistics. Means, standard deviations, and ranges were calculated for
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chronological age, age at menarche and menopause, and pre- and post-test physiological
measurements of weight, height, BMI, and blood pressure. Additional descriptive
statistical values were obtained for sample characteristics including race, education, marital
and employment status, presence of hypertension or diabetes, smoking status, exercise
status, relevant family history, reproductive history, and characteristics of participants
based upon the American Heart Association’s cardiovascular risk factors.
Aim one, describe HRV in postmenopausal women, was addressed by performing
descriptive analyses for group mean data on each individual HRV value to obtain means,
standard deviations, and ranges of scores at baseline and following six weeks of hormone
replacement therapy. These values were compared to mean HRV values for healthy female
controls (Cashion, 1988).
Aim two was to describe the differences in HRV in postmenopausal women before
and after six weeks of hormone replacement therapy. Assuming a normal distribution of
variables, paired t-tests were performed on pre- and post-test HRV mean values. Statistical
significance of alpha 0.05 established statistical significance with alpha values £  0.10 ³
0.05 used to indicate a statistical trend.
Aim three was to describe HRV relative to selected cardiovascular risk factors
before and after six weeks of hormone replacement therapy. Pearson product-moment or
Spearman’s Rho correlation coefficients were calculated on selected factors to measure the
strength of linear relationship between each factor and each HRV variable. Paired t-tests
were done to investigate differences between pre- and post-tests HRV mean values across
race, presence/absence of hypertension, and years of menopause.
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Study Assumptions
The assumptions for this study were embedded in the philosophical framework
described in chapter one. The following assumptions were the impetus for the evolution of
and, ultimately, implementation for this investigation:
1. Menopause is a multi-dimensional event which marks a biological
transition in women’s natural process of aging. It can be investigated under
a biomedical paradigm as a reproductive hormonal deficiency.
2. Determining the definitive nature of reproductive hormone effects on
women is difficult because of the many conflicting factors which
concurrently affect both the physiological and psychological response to the
menopausal event.
3. Considering both the benefits and risks, hormone replacement therapy is a
highly effective therapeutic intervention in treating cardiovascular
symptomatology, preventing cardiovascular morbidity, and reducing
cardiovascular mortality caused by the decrease in reproductive hormones.
4. The frequency and time domains of heart rate variability are relevant
measures to assess cardiovascular morbidity and predict CV mortality.
5. Six weeks of HRT will alter a response in heart rate variability because of
its attenuation of pressor and neurohormonal responses and its alteration of
sympathetic control (Collins & Beale, 1996).
Study Limitations
A major limitation to this study was recruitment of participants. For individuals in
some of the geographical locations, transportation to the enrollment site to initiate testing
56
was a limiting factor for participation. Many did not drive and depended on family
members or friends to transport them to the clinic. The occurrence of several major
holidays during the data collection period also hindered recruitment. Committing to six
weeks of study participation and the need to obtain transportation back to the clinic for
retesting could have been a deterring factor in the decision to participate.
Subjects were primarily recruited from individuals who presented to clinics for
healthcare intervention. Participants were considered “healthy” at the time of their visit,
returning for medication refills or follow-up on their chronic illnesses rather than for an
acute, episodic illness. Although they were representative of a clinically-relevant population
within a family practice setting, results can not be generalized to the whole population of
menopausal women, nor to all PMW who are treated at a community-based clinic.
Additionally, the small sample size limits the use of inferential statistics in the analyses and,
additionally, generalization of the results.
The drug treatment intervention caused side effects such as break-through vaginal
bleeding and breast tenderness for some participants. For two individuals, these side
effects caused them to withdraw from the study. Additionally, several women did not
comply with the instructions to mark the Drug Documentation Calendar. Therefore, report
of compliance was by self-report of memory recall or the count of remaining tablets.
Minimal documentation was available from the literature to determine the length of
time needed for an effect of HRT to be observed on HRV. The drug intervention protocol
chosen for this study was for six weeks, based on results from a previous study by Collins
and Beale (1996) showing neurohormonal changes and pressor responses following six
weeks of HRT administration. This time frame may not have been an adequate amount of
time to determine if a significant effect on HRV may result in response to HRT.
Control of intervening factors such as age and concomitant disease was done by
recording individual participant factors and including the presence or absence of selected
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factors during the study analyses. Medications which might effect cardiac autonomic
function were also recorded. However, other intervening factors such as new stresses
occurring during the study period could not.
The small size, enrollment of PMW with a large number of confounding variables
such as multiple CV risk factors and chronic disease, and use of an exploratory design with
multiple analyses considering a significant trend using a p-value=£ .10, limit interpretation
of results and require a cautious review of findings.
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CHAPTER IV
RESULTS
The purpose of this study was to investigate the effect of postmenopausal hormone
replacement therapy on cardiac autonomic function. This chapter presents the results of this
investigation which utilized an experimental pre-test/post-test design to explore the effects
of six weeks of hormone replacement therapy (estrogen/progesterone combined continuous
therapy) on heart rate variability. Twenty-six postmenopausal women between the ages of
45-60 were recruited with 24 women completing the six week study.
Three specific aims were identified for conducting this study: (1) describe heart rate
variability for postmenopausal women, ages 45-60; (2) describe the differences in heart rate
variability for postmenopausal women before and after six weeks of hormone replacement
therapy; and, (3) describe heart rate variability for postmenopausal women relative to
selected cardiovascular risk factors before and after six weeks of hormone replacement
therapy.
Descriptive data which include demographic, medical, and social characteristics of
the sample are presented first, followed by further descriptive analyses of pre-and post-test
HRV group means. Paired t-tests were used to compare differences between mean values
for pre- and post-tests. Using Pearson product-moment or Spearman Rho correlation
coefficients, relationships across cardiovascular risk factors were investigated, and  paired
t-tests were conducted to further investigate differences between pre- and post-test for the
total sample across selected cardiovascular risk factors.
Comparison of mean HRV values for PMW participating in this study were made
with mean HRV values for healthy female controls. Testing and data analyses for the
control group and for this current study were conducted at the Physiologic Function
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Laboratory at a Mid-South research facility. Validity and reliability studies conducted by
Cashion (1998) have provided normative data for HRV values within healthy controls and
identified values which are borderline and abnormal. Healthy female controls, a subset of
the total sample (N=158), were used as comparison to PMW in this study. This group
included 28 (24%) Blacks, 86 (74%) Whites, and 3 (2%) others with a mean sample age of
35.6 ± 11.8. Normative data for the total sample are included in Appendix G.
Further statistical analyses were conducted to examine the differences in HRV
group means across the various cardiovascular risk factors. However, because of the
exploratory design of this study and the small sample size, use of inferential statistics was
limited and results of further analyses should be reviewed and interpreted with caution.
These analyses were not included in the results chapter, but can be reviewed in Appendices
H - J.
Sample Description
Tables two through seven present a description of the study participants across
demographic, medical, social, reproductive history, and physical characteristics.
Additionally, participants are described according to their cardiovascular risk factors as
defined by the American Heart Association. Data are categorized by sample and across race
to provide a broader description of participants.
   Demographic Data   
The demographic data for the sample are presented in Table 2. The 24 women
ranged in age from 45-60, mean age of 54.92, with 15 (63%) Blacks and 9 (37%) Whites.
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Table 2
Demographic Characteristics of Postmenopausal Women
Variable Sample (N=24) Blacks (n=15) Whites (n=9)
mean n % mean n % mean n %
Age Mean 54.9 54.27 54.92
SD 4.45 4.15 4.45
Range 45-
60
47-60 45-60
< 55 10 42 8 53 2 22
³  55 14 58 7 47 7 78
Educational Status
No High
School
(HS)
Diploma
10 42 8 53 2 22
Completed
HS*
14 58 7 47 7 78
Marital Status
Not Married 15 63 12 80 3 33
Married 9 47 3 20 6 67
Employment Status
Unemployed 9 38 5 33 4 5
Employed
Full or Part
Time
15 62 10 67 44 56
* Three women in this group had completed college.
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    Medical/Social History   
Current medical and social characteristics are identified in Table 3. Seventeen (71%)
women presented with concomitant disease, including coronary artery disease (1-4%),
diabetes mellitus (8-33%), and hypertension (11-46%). Four (17%) of the women
presented with both diabetes mellitus and hypertension. Three (13%) women were
diagnosed with hypothyroidism. Only 7 (29%) women were on no prescribed medications.
Other women were taking a variety of prescribed drugs for disease management including
insulin (n=4), oral sulfonylureas (n=2), antihypertensives (calcium channel blockers, n=2;
beta blockers, n=1; diuretics, n=3; ACE inhibitors, n=7; vasodilators, n=2),
antidepressants (n=4), hypolipidemics (n=3, and thyroid supplements (n=3). Nine (38%)
women were prescribed a multi-drug regimen such as antihypertensive, hypolipidemic, and
oral sulfonylurea.
Social history was obtained by self report on the demographic form. Nine (37%) of
the women were current smokers. Of the 15 (63%) non-smokers, 4 had smoked in the
past, but all had been non-smokers for > 17 years. A larger percentage of Caucasian
women (44%) compared to Black women (33%) were current smokers. However,
Caucasian women (67%) reported more involvement in planned exercise than did Black
women (47%). Intake of alcohol was denied by 13 (54%) of the women. Of those women
who reported alcohol intake, 7 (29%) identified their intake as occasional, and 4 (17%)
identified their intake as frequent.
Exercise was defined in the study as planned physical activity such as walking or
bicycle riding, in contrast to unplanned activity which resulted during employment,
housework, or gardening, or minimal/no physical activity. Of the 24 women, 13 (54%)
reported that they engaged in planned physical activity compared to 11 (36%) who denied
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participation in planned physical activity. Of the 11 women who denied participation, 8
were employed outside the home.
Review of self-reported family medical history identified 8 (33%) women reporting
family members with cardiovascular disease, 14 (58%) with diabetes mellitus, and 11
(46%) with hypertension. Black women reported a higher percentage of family history of
HTN (47% compared to Whites, 33%), while Whites reported a higher percentage of
family history of coronary artery disease (56% compared to Blacks, 27%).
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Table 3
Medical and Social Characteristics of Postmenopausal Women
Variable Sample
(N=24)
Blacks
(n=15)
Whites
(n=9)
n % n % n %
Medical History Variables
Diabetes 8 33 5 33 3 33
No Diabetes 16 67 10 67 6 67
Hypertension 11 46 9 60 2 22
No Hypertension 13 54 6 40 7 78
Diabetes and Hypertension4 17 4 27 0 0
Coronary Artery Disease 1 4 0 0 1 11
Social History Variables
Current Smoker 9 37 5 33 4 44
Non-Smoker/Quit > 10 yrs15 63 10 67 5 56
Alcohol Intake: None 13 54 8 53 5 56
Alcohol Intake: Occasionally7 29 5 33 3 33
Alcohol Intake: Frequently4 17 2 14 2 21
Planned Exercise 13 54 7 47 6 67
No Planned Exercise 11 36 8 53 3 33
Family History Variables
Coronary Artery Disease 8 33 4 27 5 56
Diabetes 14 58 9 60 5 56
Hypertension 11 46 7 47 3 33
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   Reproductive History   
Characteristics of the sample by reproductive history are summarized in Table 4.
The mean age of menarche in the sample was 12.5 years (SD=0.93) with no difference
across race. Mean age at menopause was 46.4 years (SD=5.99; Range=32-55) which is
lower than the national average of 51 years. Seventeen (71%) women experienced
menopause at an age less than 51 years. Three of these women experienced premature
menopause at an age less than 40 years (Blacks, n=2; Whites, n=1). Seven (29%) women
reported age at menopause between 51-55 years (Mean=52.4; SD=1.4). The mean age for
onset of menopause was the same across race.
The mean number of years of menopause for all women during study participation
was 8.64 years (SD=5.35; Range=1-21 years). Thirteen (54%) women were menopausal
less than nine years (Mean=4.86; SD=2.48; Range=1-8 years), and 11 (46%) women were
menopausal nine years or greater (Mean=13.45; SD=3.88; Range=9-21 years). A
difference was observed across race for this variable. Blacks in this sample averaged 7.93
(SD=5.71; Range=2-21 years) years of menopause compared to the average number of
years of menopause for Whites of 9.89 years (SD=5.09; Range=1-19 years).
Of the 24 women participating in the study, 13 (54%) women reported no previous
use of hormone replacement therapy (HRT). Eleven (44%) women reported previous use
of HRT, with nine (38%) women having stopped HRT between three to six months prior
to study participation, and two (8%) women who completed an eight week wash-out period
of no HRT use prior to study enrollment.
The inclusion criteria for study participation was based upon having a Follicle
Stimulating Hormone (FSH) level of > 30 mIU/ml and Estradiol level < 30 pg/ml. The
mean FSH level for the total sample was 61.91 (SD=21.32), and the mean Estradiol level
was 5.32 (SD=7.49).
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Table 4
Characteristics of Postmenopausal Women by Reproductive History
Variable Sample (N=24) Blacks (n=15) Whites (n=9)
Mean n % Mean n % Mean n %
Age at Menarche
Mean 12.5 12.6 12.33
SD 0.93 .91 1.0
Range 11-15 11-15 11-14
Age at Menopause
Mean 46.42 46.53 46.22
SD 5.99 5.7 6.82
Range 32-55 35-55 32-53
< age 511 17 71 12 80 5 56
³  age 51 7 29 3 20 4 44
Years of
Menopause
Mean 8.64 7.93 9.89
SD 5.35 5.71 5.09
Range 1-21 2-21 1-19
< 9 years 4.86 13 54 10 67 3 33
³  9 years 13.45 11 46 5 33 6 67
Past History of HRT Use
No Past Use 13 54 6 40 7 78
Past Use2 11 46 9 60 2 22
(table continues)
66
Table 4 (continued)
Variable Sample (N=24) Blacks (n=15) Whites (n=9)
Mean n % Mean n % Mean n %
FSH Levels
Mean 61.91 60.31 64.57
SD 21.32 19.03 25.70
Range 30.73-102.89 31-95.7 30.73-102.89
Estradiol Levels
Mean 5.32 4.94 5.96
SD 7.49 4.90 10.89
Range 1.51-34.09 1.5-15.37 2.0-34.093
1Three women experienced premature menopause < age 40 (Blacks=2; Whites=1).
2Two women completed an eight week wash-out period prior to study enrollment .
3One woman presented with an estradiol level of 34.09. She was included in the study
because her FSH level was 40 and she had been amenorrheic for 7 years. Her HRV levels
were consistent with other PMW in the study and below the group mean for each value.
   Physical Characteristics   
Tables five and six identify height, weight, Body Mass Index (BMI), and blood
pressure and delineation of health risk for this sample based upon BMI . The mean height
for the sample was 64.67 inches (SD=2.70; Range=60-71). At enrollment, the mean
weight for the sample was 166.92 pounds (SD=43.88; Range=108-281). The mean weight
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for Blacks (169.53; SD=50.56) was similar to Whites (162.56; SD=30.46), however the
upper limit of the ranges differed by 57 pounds (Blacks=281; Whites=224) at pre-test and
by 62 pounds at post-test (Blacks=283; Whites=221). The mean weight at post-test was
167.58 (SD=43.86; Range=111-283). Nine (37%) women demonstrated a decrease or no
change in their weight. An increase in weight was documented in 15 of the women with an
average weight gain for these women of 3.27 pounds.
Body Mass Index was calculated at a mean of 28 kg/m2 on enrollment (SD=7.5;
Range=18-45) with no significant change at post-test. This value identifies the sample to be
at a high health risk based upon weight (Lerman, 1997). Seven (29%) women presented
with a BMI of < 25 representing a low health risk. Nine (38%) women presented with
BMI’s between 25 and < 30 representing a moderate to high health risk. A very high health
risk was identified for eight (33%) women who presented with a BMI of ³  30 (Blacks,
n=5; Whites, n=3). Three (13%) Blacks would be classified as morbidly obese based upon
their BMI of > 40.
The mean systolic blood pressure (SBP) of the sample at enrollment was 132.25
mm/Hg (SD=19.04; Range=106-190), and the mean diastolic blood pressure (DBP) was
82.92 mm/Hg (SD=7.80; Range=70-100). Ten (42%) women (Blacks, n=7; Whites, n=3)
presented with elevations of systolic or diastolic blood pressures categorized as Stage One
Hypertension or greater with a SBP ³  140-159 or a DBP ³   90-99. One of these woman
(Black, age 60, with both HTN and DM) presented with Stage Three Hypertension with a
BP of 190/100. Nine of the women were currently taking antihypertensive medication.
Mean systolic/diastolic blood pressures at post-test were 135.67 and 83 mm/Hg. Seven
women presented with elevations of SBP ³  140-159 or a DBP ³   90-99. The woman with
Stage Three HTN presented with a BP of 140/90 at re-testing.
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Table 5
Mean Height, Weight, Body Mass Index, and Blood Pressure Values of
Postmenopausal Women
Variable Sample (N=24)Blacks (n=15)Whites (n=9)
Height (in.)
Mean 64.67 64.53 64.89
SD 2.70 2.70 2.85
Range 60-71 60-71 61-68
Weight (lb.)
Pre-Test
Mean 166.92 169.53 162.56
SD 43.48 50.56 30.46
Range 108-281 108-281 122-224
Post-Test
Mean 167.58 169.93 163.67
SD 43.86 51.28 30.04
Range 111-283 111-283 124-221
Body Mass Index (kg/m2)1
Pre-Test
Mean 28.00 28.6 27
SD 7.50 9.11 3.84
Range 18-45 18-45 22-35
Post-Test
Mean 28.08 28.73 27
SD 7.72 9.48 3.46
Range 18-46 18-46 23-34
(table continues)
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Table 5 (continued)
Variable Sample
(N=24)
Blacks (N=15) Whites
(N=9)
Systolic blood Pressure
(mm/Hg)
Pre-Test
Mean 132.25 134.13 129.11
SD 19.04 20.18 17.67
Range 106-190 110-190 106-158
Post-Test
Mean 135.67 137.33 132.89
SD 17.43 18.25 16.65
Range 96-170 96-170 112-160
Diastolic Blood Pressure (mm/Hg)
Pre-Test
Mean 82.92 83.33 82.22
SD 7.80 9.37 4.52
Range 70-100 70-100 78-90
Post-Test
Mean 83.00 83.47 82.22
SD 8.77 10.27 5.95
Range 60-96 60-96 74.94
1BMI is a measure of weight for height. It can be calculated from prepared charts which
appropriately evaluate individuals between the ages of 19 and 70. Normal BMI is
approximately 22 kg/m2. A BMI of ³  27 kg/m2  is related to high to extremely high health
risk (Lerman, 1997).
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Table 6
Body Mass Index and Health Risk of Postmenopausal Women
Body Mass
Index
Health Risk1 Sample
(N=24)
Blacks
(n=15)
Whites
(n=9)
n % n % n %
18 to <25 Low 7 29 5 33 2 22
25 to <27 Moderate 5 21 1 7 4 45
27 to <30 High 4 17 3 20 1 11
³  30 Very High 8 33 6 40 2 22
1Body Mass Index is related to morbidity and mortality caused by obesity and is an
indicator of health risk.
   Source   :  Lerman, R. H. (1997). Obesity: An escalating problem: Addressing the genetic
and environmental factors.    C ntemporary Internal Medicine, 9,  14-21.
   Cardiovascular Risk Factors   
Table seven characterizes the sample by presence of risk factors identified by the
American Heart Association. Sixteen (67%) women (Blacks, n=11; Whites, n=5), reported
a family history of cardiovascular disease, either coronary heart disease or hypertension.
Presence of contributing factors were identified in eight (33%) of the women who had
diabetes mellitus and 17 (71%) women who had Body Mass Indexes of > 25 which placed
them at or above moderate health risk. Three women were morbidly obese. Nine (38%)
women were identified with modifiable risk factors of smoking, 11 (46%) with
hypertension, and 11 (46%) who were non-exercisers.
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Table 7
Characteristics of Postmenopausal Women Based Upon the American Heart
Association’s Cardiovascular Risk Factors1
Variable
Sample
 (N = 24)
Blacks
(n=15)
Whites
(n=9)
n % n % n %
Non-Modifiable
Black 15 63 15
Family History of Cardiovascular
Disease (CAD or HTN)
16 67 11 73 5 56
Modifiable
Cigarette Smoking 9 38 5 33 4 44
Hypertension 11 46 9 60 2 22
Non-Exerciser 11 46 8 53 3 33
Contributing Factors
Diabetes Mellitus 8 33 5 33 3 33
Obesity (Body Mass Index > 25) 17 71 10 67 7 78
1   Source:  American Heart Association. (1998). Risk factors and coronary heart disease.
[On-Line]. Available: http://www.amhrt.org/Heart-and-Stroke-A-Z-Guide/riskfact.html.
Aim One
Aim one was to describe heart rate variability (HRV) in postmenopausal women
between the ages of 45-60. Twenty-four hour ambulatory Holter monitoring was used to
collect data for analysis of HRV. The frequency domain values delineate between
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sympathetic and parasympathetic cardiac autonomic function, and the time domain values
reflect cardiac autonomic balance. Time domain values of pNN50 and rMSSD further
reflect vagal influences within autonomic activity.
The frequency and time domains of HRV for the sample of 24 postmenopausal
women are summarized in tables eight and nine using descriptive statistics to identify
means and standard deviations for each HRV variable at baseline and following six weeks
of hormone replacement therapy. Normative data established from analysis of HRV from
healthy female controls (mean age=35.6 ± 11.8) tested through the Physiologic Function
Laboratory (Cashion, 1998) are included in the tables for comparison of values. In
addition, mean HRV values for PMW across race are also summarized.
   Pre-Test Heart Rate Variability
Means for all HRV values were lower for study participants than the HRV means
for healthy female controls with all frequency domain mean values less than one SD below
the values for healthy female controls. The mean value for Low Hertz within the sample
was borderline abnormal, as established by normative values for the Physiologic Function
Laboratory (Cashion, 1998). This low value was consistent across race. All other mean
values in the frequency domains, and all time domain mean values, were within the normal
range established for healthy controls, with pNN50, rMSSD, SDNN, and SDANN mean
values within one SD of the mean for healthy female controls. White PMW, when
compared to Black PMW, demonstrated the pattern identified by Huikuri et al. (1996) and
Rosano et al. (1997) as better parasympathetic mediation represented by a higher High
Hertz and a lower Low/High Ratio.
SDNN values of less than 50 ms. have been used as a predictors for cardiovascular
mortality. Survivors of acute myocardial infarction had approximately a four-fold increased
risk of dying during post-recovery when compared with participants whose SDNN value
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was more than 100 ms (Kleiger, 1987). In this sample of 24 postmenopausal women, only
one Black woman, age 53, non-smoker with hypertension and nine years postmenopause
presented with values approaching the critical level of 50. Her pre-test SDNN value was
59, decreasing to 52 on post-test.
Two PMW presented with all HRV values near or above, the values for healthy
female controls. Both were Black, ages 47 and 56, and were postmenopausal less than nine
years. The 56 year old woman had concomitant disease of both diabetes mellitus and
hypertension. Nine (38%) PMW, five Blacks and four Whites, demonstrated baseline
HRV values which were abnormal based on normative data established for healthy
controls. Four (44%) were smokers and four (44%) were non exercisers. Seven (78%)
were postmenopausal ³  9 years.
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Table 8
Pre-Test Mean Values for Heart Rate Variability for Postmenopausal Women
HRV Values
Mean Values
for Healthy
Controls1
Sample
(N=24)
Blacks
(n=15)
Whites
(n=9)
Frequency Domains
Total Hertz Mean 7.16 6.22 6.18 6.29
SD 0.61 0.80 0.08 0.08
Low Hz Mean 6.31 5.15 5.15 5.16
SD 0.64 0.89 0.09 0.09
High Hz Mean 5.18 4.11 4.07 4.17
SD 0.88 1.07 1.09 1.09
Lo/Hi Ratio Mean 1.30 1.31 1.29
SD 0.22 0.19 0.27
Time Domains
pNN50 Mean 10.80 3.80 3.65 4.11
SD 8.12 3.92 3.96 4.00
rMSSD Mean 32.00 20.67 20.20 21.57
SD 13.00 8.21 8.27 7.99
SD Mean 56.00 38.00 37.93 38.07
SD 14.00 13.18 14.86 13.67
SDNN Mean 129.00 101.92 103.93 100.79
SD 31.00 27.19 32.24 22.38
SDANN Mean 115.00 93.17 95.27 91.71
SD 31.00 24.88 29.57 19.03
1 Based on data from Physiologic Function Laboratory testing. Sample = 118 women,
mean age = 35.6 ± 11.8; range: 18-61 years. Blacks=24%; Whites=74%
Source: Cashion, A. (1998). Twenty-four hour heart rate variability measures in healthy
controls. Unpublished raw data, University of Tennessee, Memphis.
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   Post-Test Heart Rate Variability   
The frequency and time domains for heart rate variability collected on post-test
following six weeks of postmenopausal hormone replacement therapy are summarized in
Table 9. Mean post-test values for PMW remained lower than mean values for healthy
female controls, but were within the normal mean ranges for HRV (see Appendix G). Post-
test mean values improved over pre-test mean values for Total Hertz, Low Hertz, High
Hertz, pNN50, rMSSD, and SD. Frequency domain values of Total Hertz and time domain
values of pNN50 and rMSSD were at or within one SD from the mean. Mean values for
SDNN and SDANN decreased from pre-test mean values, but were at or above one SD
from the mean value for healthy female controls. Low Hertz, High Hertz, and SD remained
below one SD from the mean values for healthy female controls. Mean value for Low Hertz
improved from borderline abnormal to within the range of normal as established by
normative data for healthy controls.
Black PMW demonstrated improvement in seven of the nine HRV values. SDNN
and SDANN decreased as was reflected in total sample means, but values were within one
SD of the mean for healthy controls. Black PMW reflected an improvement in
parasympathetic mediation with an increase in High Hertz and a decrease in Low/High
Ratio. In contrast, White PMW improved in only three variables, Low Hertz, pNN50, and
SD. Decreases in total sample mean values were noted for Total Hertz and High Hertz,
with an increase in Low/High Ratio. SD improved minimally, but rMSSD, SDNN, and
SDANN all decreased from pre-test values, with SDNN decreased below one SD from the
mean for healthy controls.
Seven (29%) women (Blacks, n=4; Whites, n=3) demonstrated individual post-test
values which were abnormal compared to normative data for healthy controls. Five (71%)
of these women were ³  55 years of age, suggesting an age effect. Additionally, five (71%)
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were smokers and four (57%) were non-exercisers by self-report. Five (71%) of the
women had been postmenopausal ³  9 years.
Two women had low SDNN values (58 and 56) on post-test. SDNN is a predictor
of cardiac mortality in survivors of acute myocardial infarction when below 50 ms. Only
one of these women had a low value (59) on pre-test. The other woman, White, smoker
with diabetes, seven years postmenopausal, decreased in SDNN value from 78 on pre-test
to 56 on post-test.
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Table 9
Post-Test Mean Values for Heart Rate Variability for Postmenopausal Women
HRV Values
Mean Values
for Healthy
Controls1
Sample
(N=24)
Blacks
(n=15)
Whites
(n=9)
Frequency Domains
Total Hertz Mean 7.16 6.38 6.49 6.19
SD 0.61 0.78 0.64 0.98
Low Hz Mean 6.31 5.39 5.47 5.26
SD 0.64 0.82 0.69 1.04
High Hz Mean 5.18 4.21 4.40 3.90
SD 0.88 1.07 0.91 1.28
Lo/Hi Ratio Mean 1.33 1.27 1.42
SD 0.23 0.19 0.28
Time Domains
pNN50 Mean 10.80 4.55 4.47 4.69
SD 8.12 5.15 4.72 6.10
rMSSD Mean 32.00 21.83 22.13 21.33
SD 13.00 10.16 8.99 12.45
SD Mean 56.00 39.46 40.27 38.11
SD 14.00 12.73 12.03 14.47
SDNN Mean 129.00 98.38 100.40 95.00
SD 31.00 27.27 30.99 20.92
SDANN Mean 115.00 88.58 91.00 84.56
SD 31.00 26.61 30.79 18.64
1 Based on data from Physiologic Function Laboratory testing. Sample = 118 women,
mean age = 35.6 ± 11.8; range: 18-61 years. Blacks=24%; Whites=74%
Source: Cashion, A. (1998). Twenty-four hour heart rate variability measures in healthy
controls. Unpublished raw data, University of Tennessee, Memphis.
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Aim Two
Aim two was to describe the differences in heart rate variability for postmenopausal
women before and after six weeks of hormone replacement therapy. A summary of
changes in mean HRV values between pre- and post-testing is given in Tables 10 and 11.
Paired t-tests were used to compare differences between the means which showed increases
in post-test values over pre-test values for seven of the variables. Although no increase was
statistically significant at the p £  0.05 level, both Low Hertz (p=0.06) and pNN50
(p=0.10) had increases in mean values which approached significance (p = £  0.10 > 0.05).
Across race, significant differences were observed between pre- and post-test mean
values. For Black PMW, significant differences (p = £  0.05) were observed for Total
Hertz, Low Hertz, High Hertz, and rMSSD. Although not significant, improvement was
also noted for pNN50 and SD. Improvement in parasympathetic mediation was observed
by noting the increase in High Hertz and the decrease from 1.31 to 1.27 in the Low/High
Ratio. No significant improvement were observed across post-test HRV values for White
PMW. In contrast to Black PMW, White women significantly (p = £  0.05) increased in
Low/High Ratio and decreased in High Hertz, demonstrating poorer parasympathetic
mediation and higher sympathetic activity when compared to pre-test values.
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Table 10
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women
HRV Variables
Mean Values for
Healthy Female
Controls1
Pre-Test Post-Test Change
Score
p2
Frequency Domains
Total Hz Mean 7.16 6.22 6.38 + 0.16 0.13
SD 0.61 0.80 0.78
Low Hz Mean 6.31 5.15 5.39 + 0.24 0.06
SD 0.64 0.89 0.82
High Hz Mean 5.18 4.11 4.21 + 0.10 0.42
SD 0.88 1.07 1.07
Lo/Hi Ratio Mean 1.30 1.33 ­ 0.39
SD 0.22 0.23
Time Domains
pNN50 Mean 10.80 3.80 4.55 + 0.75 0.10
SD 8.12 3.92 5.15
rMSSD Mean 32.00 20.67 21.83 + 1.16 0.19
SD 13.00 8.21 10.16
SD Mean 56.00 38.00 39.46 + 1.46 0.25
SD 14.00 13.18 12.73
SDNN Mean 129.00 101.92 98.38 - 3.54 0.23
SD 31.00 27.19 27.27
SDANN Mean 115.00 93.17 88.58 - 4.59 0.17
SD 31.00 24.88 26.61
1 Based on data from Physiologic Function Laboratory testing. Sample = 118 women,
mean age = 35.6 ± 11.8; range: 18-61 years. Blacks=24%; Whites=74%.
   Source:   Cashion, A. (1998). Twenty-four hour heart rate variability measures in healthy
controls. Unpublished raw data, University of Tennessee, Memphis.
2 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 11
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Between and Within Demographic Variable of Race
HRV Variables  Demographic Variables
Blacks (n = 15) Whites ( n = 9)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.18 6.49 .01 6.29 6.19 ¯ .60
SD 0.08 0.64 0.08 0.98
Low Hz Mean 5.15 5.47 .03 5.16 5.26 .69
SD 0.09 0.69 0.09 1.04
High Hz Mean 4.07 4.40 .01 4.17 3.90 ¯ .30
SD 1.09 0.91 1.09 1.28
Lo/Hi Mean 1.31 1.27 ¯ .11 1.29 1.42 ­ .05
Ratio SD 0.19 0.19 0.27 .28
Time Domains
pNN50 Mean 3.65 4.47 .16 4.11 4.69 .44
SD 3.96 4.72 4.00 6.10
rMSSD Mean 20.20 22.13 .05 21.57 21.33 ¯ .95
SD 8.27 8.99 7.99 12.45
SD Mean 37.93 40.27 .12 38.07 38.11 1.0
SD 14.86 12.03 13.67 14.47
SDNN Mean 103.93 100.40 ¯ .36 100.79 ¯  95.00 ¯ .48
SD 32.24 30.99 22.38 20.92
SDANN Mean 95.27 91.00 ¯ .32 91.71 ¯  84.56 ¯ .38
SD 29.57 30.79 19.03 18.64
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Aim Three
Aim three was to describe heart rate variability for postmenopausal women relative
to selected cardiovascular risk factors before and after six weeks of hormone replacement
therapy. To measure the strength of linear relationship between heart rate variability values
in PMW and their demographic, medical, and social characteristics, Pearson product-
moment and Spearman Rho correlation coefficients were calculated. No significant
relationships were observed between HRV values and race and age. However an inverse
response was seen between all HRV values and increasing age. Across the medical
variables, a significant relationship between HTN and Low Hertz/pre-test was found. No
other significant relationships were identified between HRV variables and HTN or with
diabetes mellitus. Although not significant, inverse relationships were noted between HTN
and all HRV values except pNN50 post-test. Also, although not significant, inverse
relationships were noted between DM and post-test HRV values.
 Inverse relationships were noted between smoking and all HRV values. Significant
relationships (p = £ .10 ³  .05) were observed between smoking and post-test HRV values
of Total Hertz, Low Hertz, High Hertz, and pNN50. No significant relationships were
found across exercise status. Significant inverse relationships or trends were found
between years of menopause and all frequency domain values and the time domain value of
SD. Table 12.1 summarizes the relationships across selected cardiovascular risk factors and
pre- and post-test HRV.
Table 12.2 summarizes tests to investigate differences across race relative to
selected cardiovascular risk factors. T-tests or chi square, as appropriate for data, were
used. Trend differences at p = £ .10 ³  .05 were found for HTN (p=.07).
Table 13 summarizes differences between the pre- and post-test scores across the
medical variable of HTN. Eleven PMW (Blacks, n=9; Whites, n=2) reported a diagnosis of
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HTN with pharmacological treatment comprised of varied, and often multiple,
antihypertensive drugs (calcium channel blockers, n=2; beta blockers, n=1; diuretics, n=3;
ACE inhibitors, n=7; vasodilators, n=2). Women with HTN demonstrated significant  (p =
£ .10 ³  .05) improvement in Low Hertz and the time domain values representing vagal
influences of pNN50 and rMSSD. Low Hertz increased from an abnormal value, and Total
Hertz, although not demonstrating significance, increased from an abnormal value to a
value within normal range. In contrast, no significant improvement in HRV values were
observed in PMW without HTN, although frequency domains, pNN50, and SD
demonstrated improvement in post-test values over pre-test.
Across years of menopause, women (44%) ³  9 years menopausal (Blacks, n=5;
Whites, n=6) demonstrated significant (p = £ .10 ³ .05) improvement in Total Hertz, Low
Hertz, pNN50, and SD. In contrast, PMW < 9 years demonstrated improvement, but not
significantly,  in post-test HRV values of frequency domains, pNN50, rMSSD, and SD
(see Table 14).
Table 12.1
Relationship Between Pre- and Post-Test Heart Rate Variability for Postmenopausal
Women Across Sample Demographic, Medical/Social, and Reproductive History
Variables
HRV
Variables
1
Race
2
Age
3
DM
2
HTN
2
Smoke
Status
2
Exer.
Status
2
BMI
3
Age at
Meno
pause
3
Yrs of
Meno
3
Frequency Domains
Total Hz 1 .06 -.18 .13 -.29 -.18 -.05 .29 .26 -.41**
Total Hz 2 -.08 -.21 -.09 -.21 -.42** .16 .06 .19 -.37 *
Low Hz 1 -.02 -.26 .16 -.41** -.09 -.11 .27 .23 -.43**
Low Hz 2 .01 -.26 -.12 -.33 -.35* .21 .01 .23 -.43**
High Hz 1  .06 -.03 .05 -.14 -.21 -.07 .27 .33 -.35*
High Hz 2 -.15 -.17 -.01 -.08 -.38* .03 .15 .21 -.34*
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Lo/Hi
Ratio 1
-.04 -.18 .04 -.11 .29 .13 -.22 -.26 .12
Lo/Hi
Ratio 2
 .29  .03 -.02 -.21 .32 .05 -.19 -.21 .22
Time Domains
pNN50 1 .14 -.05 .04 -.21 -.30 .05 .18 .21 -.27
pNN50 2 -.12 .03 .03 .02 -.36* .03 .21 .18 .14
rMSSD 1 .08 -.03 .01 -.24 -.25 .01 .13 .26 -.31
rMSSD 2 -.10 -.02 -.02 -.03 -.31 -.01 .18 .21 -.22
SD 1 .08 -.19 .01 -.26 -.23 .02 .12 .25 -.42**
SD 2 -.01 -.09 -.01 -.19 -.30 .05 .05 .28 -.37*
SDNN 1 -.01 -.23 -.04 -.16 -.09 -.01 .26 .06 -.26
SDNN 2 -.02 -.33 -.08 -.27 -.21 -.05 .21 .01 -.27
SDANN 1 -.02 -.21 -.01 -.02 -.06 -.03 .26 .01 -.19
SDANN 2 -.02 -.36* -.06 -.31 -.12 -.11 .24 .01 -.19
1Variables are identified as 1 and 2 representing Pre-Test (1) and Post-Test (2).
2Spearman Rho Corr.:  **Significant at p = £  0.05 *Trend at p = £  0.10 > 0.05.
3Pearson’s Corr.:  **Significant at p = £ 0.05 *Trend at p = £  0.10 > 0.05.
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Table 12.2
Comparisons of Differences Across Race for Selected Cardiovascular Risk Factors
Variable Test 1, 2 p3 Blacks
(n=15)
Whites
(n=9)
Age -.921 .37 M=54.27 M=56.0
Diabetes Mellitus .002 1.0 n=5 n=3
Hypertension 3.382 .07 n=9 n=2
Smoking Status .292 .59 n=5 n=4
Planned Exercise Status .922 .34 n=7 n=6
BMI .501 .62 M=28.6 M=27
BMI by Health Risk 4.882 .18 (See Table 6)
Age at Menopause .121 .91 M=46.53 M=46.22
Age at Meno ³  51 years 1.602 .21 n=3 n=4
Years of Menopause -.841 .41 M=7.93 M=9.89
Years of Menopause ³  9 years 2.62 .11 n=5 n=6
1 t-test
2 Chi Square
3 Significant: p = £  .05 Trend: p = £  .10 ³  .05
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Table 13
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women By the Absence/Presence of Hypertension
HRV Variables  Medical Variables
Hypertension-Absent (n=13)Hypertension-Present (n = 11)
Pre-Test Post-Test p1 Pre-TestPost-Test p1
Frequency Domains
Total Hz Mean 6.48 6.56 .57 5.92 6.17 .11
SD 0.53 0.69 0.96 0.86
Low Hz Mean 5.52 5.66 .38 4.72 5.07 .09
SD 0.62 0.66 0.98 0.91
High Hz Mean 4.28 4.32 .81 3.91 4.09 .38
SD 0.82 1.01 1.31 1.17
Lo/Hi Mean 1.32 1.35 ­ .20 1.28 1.30 ­ .79
Ratio SD 0.19 0.23 0.26 0.25
Time Domains
pNN50 Mean 4.40 4.53 .83 3.09 4.58 .03
SD 4.27 5.70 3.50 4.70
rMSSD Mean 22.69 22.62 .96 18.27 20.91 .02
SD 8.35 11.23 7.72 9.19
SD Mean 40.85 41.46 .75 34.64 37.09 .16
SD 9.79 12.00 16.18 13.72
SDNN Mean 104.62 103.08 ¯ .69 98.73 92.82 ¯ .23
SD 24.80 24.65 30.70 30.31
SDANN Mean 94.23 93.69 ¯ .90 91.91 82.55 ¯ .07
SD 24.01 24.05 26.00 29.34
1Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 14
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women by Number of Years of Menopause
HRV Variables Years of Menopause
³  9 years (n = 11) < 9 years (n = 13)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 5.85 6.13 .07 6.54 6.60 .68
SD 0.76 0.83 0.70 0.70
Low Hz Mean 4.68 5.14 .01 5.56 5.61 .76
SD 0.80 0.89 0.76 0.72
High Hz Mean 3.69 3.86 .44 4.46 4.51 .76
SD 1.11 1.08 0.92 1.00
Lo/Hi Mean 1.33 1.38 ­ .44 1.27 1.28 ­ .76
Ratio SD 0.27 0.26 0.18 0.21
Time Domains
pNN50 Mean 2.52 3.62 .08 4.88 5.35 .51
SD 3.86 5.60 3.77 4.82
rMSSD Mean 17.64 19.27 .16 23.23 24.00 .16
SD 8.46 11.12 7.34 9.16
SD Mean 31.64 34.45 .07 43.38 43.69 .88
SD 9.67 11.82 13.67 12.32
SDNN Mean 93.55 90.27 ¯ .43 109.00 105.23 ¯ .43
SD 18.50 18.29 31.84 32.18
SDANN Mean 87.27 82.36 ¯ .39 98.15 93.95 ¯ .39
SD 16.69 19.00 29.93 31.48
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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CHAPTER V
DISCUSSION, RECOMMENDATIONS, AND CONCLUSIONS
A biomedical conceptual framework was used for this study, incorporating the
construct of menopause and the two concepts of hormone replacement therapy and heart
rate variability. Chapter five provides a discussion on the findings of the study and factors
which may have influenced the results and the interpretation of results. A brief overview of
the study is given, followed by identification of sample characteristics and methodology,
and finally a discussion of each study aim.
The purpose of this study was to examine the effect of postmenopausal hormone
replacement therapy on cardiovascular autonomic function (CAF) in women between the
ages of 45-60. Analysis of 24-hour heart rate variability was used to quantify CAF and to
address three specific study aims:
1. Describe heart rate variability for postmenopausal women, ages 45-60
2. Describe the differences in heart rate variability for postmenopausal women before
and after six weeks of hormone replacement therapy.
3. Describe heart rate variability for postmenopausal women across selected
cardiovascular risk factors before and after six weeks of hormone replacement therapy.
To address study aims, an exploratory, pre-test/post-test experimental design with
each woman serving as her own control was used. Postmenopausal women between the
ages of 45 and 60 (mean age=54.9; SD=4.45) were recruited for this study from two
community-based primary care clinics and a suburban church. Because previous research
on hormone replacement therapy has been criticized for selection bias which might
influence positive results, recruitment in these settings provided a diverse population of
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participants with varying ethnic and socio-economic characteristics. Twenty-six women
were enrolled in the six week intervention study with twenty-four women  (Blacks/n=15,
63%; Whites/n=9, 37%) completing the post-test following six weeks of hormone
replacement therapy.
Inclusion and exclusion criteria  for the study were liberal, unlike the related studies
by Huikuri et al. (1996) and Rosano et al. (1997) which restricted HRV analysis to women
with no documented cardiovascular disease. To provide a clinically relevant population,
postmenopausal women from a suburban church (n=4) and two community-based, family
practice settings (n=20) were recruited at the time of their visit to the clinic. Although
“healthy” at the visit, often for medication refills or follow-up only, these women presented
with a variety of concomitant diseases, such as diabetes mellitus (DM), (n=8, 33%) and
hypertension (HTN), (n=11, 46%). One woman had a past history of acute myocardial
infarction without complications three months prior to enrollment. Some women had co-
morbidity such as diabetes mellitus and hypertension (n=4), and 17 (71%) of the women
reported regular use of prescription medications. Participants reported a family history of
heart disease (n=8, 33%), DM (n=14, 58%) and HTN (n=11, 46%). Unlike the cited
studies, the sample included PMW who reported use of nicotine (n=9, 37%) and alcohol
(n=11, 46%). Although the sample was representative of PMW who reported to
community-based health clinics, use of non-random selection limited generalization of
results to the total population of postmenopausal women. The diversity of the group also
was a limitation to the study. The small sample size within subgroups hindered the ability
to control for multiple variables which feasibly could have influenced heart rate variability.
A second limitation to interpretation of study results was related to the six week
protocol for hormone replacement therapy. At the time of this study, no guidelines existed
which established the length of time necessary for HRV to respond to the administration of
HRT. Therefore, the drug intervention protocol established for this study was based on
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research reported by Collins and Beale (1996) who reported the attenuation of pressor and
neurohormonal responses and modulation of sympathetic and parasympathetic influences
on the ANS in PMW following six weeks of estrogen. Research by Rosano et al. (1997),
however, published during the course of this research, suggested that a longer period of 16
weeks may be necessary to stabilize cardiac autonomic function in symptomatic
menopausal women. After six weeks administration of HRT to study participants, varying
responses were observed across repeated HRV testing, with most values demonstrating a
nonsignificant  increase but consistent with results reported in the study by Rosano et al.
(1997). However, two time domain values consistently demonstrated decreased values.
These findings could be directly related to the limited time interval and use of HRT between
pre- and post-tests.
Huikuri et al. (1996) of Finland suggested that vagal responses to cardiovascular
autonomic regulation were lower for PMW not on estrogen replacement therapy compared
to women taking estrogen. Furthermore, they suggested that hormonal factors may
influence changes in autonomic modulation. Unique characteristics of participants in this
study which may relate to hormonal factors may also have influenced study results.
Participants reported number of years of menopause with sample mean of 8.64 ±  5.35
(range=1-21 years). Reported age at menopause (m=46.42 ± 5.99 years; range=32-55)
was lower than the 51 years reported as average age of menopause in the U.S. This finding
may indicate that the PMW in this study have had different reproductive changes and
transition into menopause, and may respond to hormones differently because of a greater
estrogen deficiency, than their age peers who experienced menopause at a later period in
their reproductive life. A possible rationale for differences in HRV values before and after
HRT administration could be suggested that HRV values for these women may be more
similar to older PMW who experienced menopause at the more typical mean age of 51.
Three of the women experienced premature menopause prior to the age of 40; no rationale
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for this occurrence could be isolated and the cause is probably multi-factorial. In addition to
low socio-economic status, the demographic characteristics for these three women were: (a)
White, smoker, DM; (b) Black, smoker, HTN; (c) Black, non-smoker, DM and HTN. All
three women were patients at the community clinic. The effect of premature menopause on
HRV has not been investigated but could have influenced study results. Although HRV
values for these women varied, the values reflected patterns demonstrated by PMW who
had experienced menopause at a later age.
The hormone combination for this study may have influenced results. Current
clinical practice guidelines dictate that postmenopausal women with intact uteri be
prescribed HRT consisting of estrogen with the addition of a progestin to prevent
endometrial hyperplasia (American College of Physicians, 1992; Barrett-Connor, 1995).
All women enrolled in the study had intact uteri; therefore, the pharmacological HRT
intervention consisted of six weeks of oral conjugated estrogen 0.625 mg and
medroxyprogesterone, 2.5 mg given in a single oral medication packaged as PremPro™, a
trademark of Wyeth-Ayerst Laboratories. A potential confounding factor in this study could
have resulted from the combination of estrogen and progesterone for HRT versus the effect
of estrogen alone on heart rate variability. Conflicting research results indicate that the
addition of a progestin may or may not attenuate the positive effects of estrogen (Grady et
al, 1992; Notelovitz, 1989). Because current clinical practice guidelines advocate progestin
in the HRT regimen for women with intact uteri, the recommended guidelines were
followed and the combination used. Compliance to the drug regimen was substantiated by
self report and may have influenced results if the protocol was not followed. Although
participants were asked to complete and return a Drug Documentation Calendar validating
their compliance, only 11 women returned the document. Twenty-two women completing
the study verbally acknowledged adherence to the protocol. Two women stated that they
had missed taking one pill during the six week study period. It is assumed that this fact had
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no negative effects on their HRV post-test values. Pre-test estradiol levels increased and
FSH levels decreased in all women following the six weeks of HRT.
Aim One
The first aim of the study was to describe heart rate variability (HRV) in
postmenopausal women between the ages of 45-60. HRV values determined by twenty-
four hour ambulatory Holter monitoring and analysis, and obtained before and after six
weeks of HRT administration, were generally within normal range, but lower than the
referent values for healthy females. Validity of this conclusion is dependent upon the
validity and appropriateness of referent group means and established values for normal,
borderline, and abnormal values. For comparison, normative values were based on sample
mean HRV values obtained from healthy female controls (n=118; mean age=35.6 ± 11.8)
tested in the same laboratory and using the same analyses and testing protocols used in
conducting this research. The age of the referent group is approximately ten years less than
that of study participants, and the differences between HRV means of these two groups
could have been influenced by this age factor. The majority of women in this study also
reported concomitant morbidity such as HTN (n=11) and DM (n=8) and use of
prescription medications which also may be factors in influencing decreased values.
Normative data based on age, disease status, and postmenopausal status have not been
established but would have provided a more relevant referent group.
   Pre-Test Heart Rate Variability
Sample means for all pre-test HRV values were lower for study participants than
the HRV means for healthy female controls with all frequency domain mean values less
than one SD below the values for healthy female controls. The mean value for Low Hertz
92
within the sample was borderline abnormal. This low value was consistent across races.
All other mean values in the frequency domains, and all time domain mean values, were
found to be within normal range. Time domain values of pNN50, rMSSD, SDNN, and
SDANN mean values were within one SD of the mean for healthy female controls. These
results were consistent with that of other researchers who suggest an inverse relationship
between HRV and age and chronic illness (Cowan et al., 1994; Liao et al., 1995; Omboni
et al., 1996; & van Ravenswaaij-Arts et al., 1993).
Consistent with study results by Liao (1995) investigating HRV across race,
descriptive comparisons across race in this study demonstrated nonsignificantly lower
HRV values for Black PMW, when compared to White PMW for all frequency domains,
pNN50, rMSSD, and SD. White PMW also demonstrated more optimum parasympathetic
activity which was reflected in their higher values for High Hertz (Whites=4.17;
Blacks=4.07) and lower value for Low/High Ratio (Whites=1.29; Blacks=1.31). Both
Blacks and Whites presented with similar cardiovascular risk factors of age (p=.37), DM
(c 2=1), smoking (c 2=.29), lack of exercise (c 2=92), BMI (p=.62), and age at menopause
(p=.41), but differed across presence of HTN (c 2=.07) and years of menopause ³  9 years
or < 9 years (c 2=.11).
   Post-Test Heart Rate Variability   
HRV sample means following six weeks of HRT continued to be lower than norms
for healthy female controls, a finding expected because of age and chronic disease
differences between the sample and referent group, but remained within normal range.
Across race, Black PMW demonstrated an increase in seven of the nine HRV values but
also showed a decrease in SDNN and SDANN as reflected by the total sample. A low
value for High Hertz with a high value for Low/High Ratio is considered indicative of
sympathetic predominance, and a change toward a higher value of High Hertz with a lower
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Low/High Ratio demonstrating a stabilization of the autonomic control of the
cardiovascular system (Rosano, 1997). Black PMW demonstrated this change from pre-
test to post-test after HRT administration. High Hertz increased from 4.07 to 4.40, and
Low/High Ratio decreased from 1.31 to 1.27 reflecting improved balance of mediation
between sympathetic/parasympathetic function. White postmenopausal women
demonstrated the opposite effect with High Hertz decreasing from 4.17 to 3.90 and
Low/High Ratio increasing from 1.29 to 1.42. The causes of these findings remain
speculative, and further research is necessary to determine if HRV responds differently to
the administration of HRT when investigated across race. Because of an increased
proportion of PMW with HTN for Black women, HTN alone, race alone, or race and HTN
together may have strong influence on the change. Years of menopause should have had a
positive effect on HRV improvement because Black women, in this sample, had fewer
years of menopause than White women, and, therefore, fewer years without endogenous
estrogen with its cardiovascular protective effects. Additional studies could help to clarify
the relationships between race, HRV, and response of hormone replacement therapy.
Because there have been no published studies which have examined the effect of hormone
replacement therapy on HRV across racial cohorts, a longitudinal, prospective study with a
larger sample size would provide the opportunity to investigate this question.
The finding of decreased values on post-test for time domain measurements of
SDNN and SDANN was not expected and had not previously been described in the
literature. Because these values are considered good measures of primary autonomic
influence on heart rate variability and reflections of circadian rhythmicity, abnormal values
may indicate pathology and predict mortality in some individuals. In this sample, the values
although decreased, continued to reflect normal values. A study with a larger sample size
and extended time frame for HRT administration is necessary to investigate whether or not
this trend would remain consistent. If researchers addressing HRV with HRT in PMW
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would report both frequency and time domain values, further investigation into the
consistency of this finding could occur.
Aim Two
Study aim two was to describe the differences in HRV for PMW before and after
six weeks of hormone replacement therapy. Paired t-tests were used to compare means
between pre- and post-tests for the total sample and by each race. For the total sample, few
significant increases in HRV were noted. Increases in Low Hertz (p=.06) and pNN50
(p=.10) demonstrated trends (p= £  .10 >.05). Increases, although not significant, were
also found for Total Hertz, High Hertz, rMSSD, and SD. On post-test, following six
weeks of HRT, nonsignificant decreases in SDNN and SDANN were found. The pattern
of pre-test HRV frequency values below one SD of the mean for healthy women, and the
time domain values higher and within one SD of the mean, may reflect that HRV time
domains could not feasibly increase sufficiently to demonstrate significant values.
White PMW showed no significant differences after six weeks of HRT. However,
significant differences were observed between pre- and post-test mean values for Black
PMW for Total Hertz (p=.01), Low Hertz (p=.03), High Hertz (p=.01) and rMSSD
(p=.05). Increases, although not significant, were observed for pNN50 (p=.16) and SD
(p=.12). Low/High Ratio showed an improvement in sympathetic/parasympathetic balance
with a decrease (p=.11) in this HRV value. These preliminary findings suggest that Black
PMW may benefit from HRT administration by improved cardiovascular tone related to
improvement of parasympathetic function. Improvement in values for Black women
occurred despite a greater proportion of women compared to White PMW with HTN and
the short period of HRT administration of six weeks. Black women, additionally, had
lower HRV values than White women at pre-test. Given that Black females have a two-fold
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risk of coronary death as compared to White women (AHA, 1988), further studies to
confirm these findings and conducted on a larger sample size, should be carried out to
clarify the benefit of HRT in this population. Hypertension as a CVD risk factor is
addressed under aim three.
Aim Three
Aim three, describe HRV for PMW relative to selected cardiovascular risk factors,
was addressed by Pearson’s product-moment and Spearman’s Rho Correlational analysis
of the relationship between HRV and sample demographic, medical, and social
characteristics. Although no significant correlation was demonstrated for race and HRV
variables, three other risk factors, HTN, smoking, and years of menopause did
demonstrate significant associations, primarily in the frequency domains. The AHA risk
factors for CVD were originally to be addressed for differences in HRV by dichotomizing
the total sample for separate analyses for each risk factor. For Black and White PMW
differences were found for HRV values, therefore, comparisons of differences across race
for selected cardiovascular risk factors were conducted using t-tests or Chi Square, as
appropriate. Because of the sample size and the risk of Type II error resulting from multiple
analyses, risk factors for which Black and White PMW did not differ, were not presented.
Differences across race was demonstrated for the risk factor of HTN (c 2 = .07) with a
larger number of Black women (n=9) compared to White women (n=2) self-reporting the
presence of HTN. Additional differences were found across years of menopause (c 2 =
.11) with Black women having fewer years of menopause (M=7.93) when compared to
White women (M=9.89).
Only HTN was found to differ across race approaching a level of significance
(p=.07). Paired t-test analyses of pre- and post-test  differences for PMW with HTN
96
(n=11) and for PMW without HTN (p=13) demonstrated significant improvement for
hypertensive women for the vagal values of pNN50 (p=.03) and rMSSD (p=.02), a trend
for Low Hertz (p=.09), and nonsignificant improvement for Total Hertz, High Hertz, and
SD. No significant differences were found in HRV for PMW without HTN, although Total
Hertz, Low Hertz, High Hertz, pNN50, and SD improved in mean values. In contrast to
these findings, pre-test differences were observed between the group with/without
hypertension. Women with HTN (n=11, 46%) demonstrated lower mean values in all
domains when compared to postmenopausal women without HTN (n=13; 54%). A
significant (p=0.02) difference was observed for Low Hertz, approaching significance
(p=0.09) for Total Hertz, and a lower mean for High Hertz, although not significant. These
findings suggest a difference in the balance between sympathetic/parasympathetic function
in PMW not on hormones with HTN compared to PMW without HTN. The women in the
HTN group were taking a variety of different antihypertensive medications, including
diuretics, calcium channel blockers, ACE inhibitors, beta blockers, and vasodilators. What
influence these pharmacological interventions had on the results requires further
investigation in a controlled study which would follow a larger cohort of PMW with and
without HTN. Because of the disproportionate number of Blacks (n=9) in comparison to
Whites (n=2), these results have to be interpreted cautiously. It is unknown if the factor
influencing the significant improvements was related to race or to disease process because
both Black PMW and women with HTN, which was primarily composed of Blacks,
demonstrated similar responses for High Hertz and rMSSD. The small sample size limited
the use of further multivariate statistical analyses to investigate relative contribution of each
risk factor.
Another differing characteristic between Black and White PMW was years of
menopause. When the total sample mean (8.64; SD=5.35) was used to dichotomize the
sample, chi square analysis indicated differences at 0.11. PMW with ³  9 years of
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menopause (Blacks, n=5; Whites, n=6) demonstrated lower pre- and post-test HRV values
in frequency domains and demonstrated significant or trends for improved values for Total
Hertz (p=.07), Low Hertz (p=.01), pNN50 (p=.08), and SD (p=.07). No significant
improvements were observed for PMW < 9 years menopausal (Blacks, n=10; Whites,
n=3). Years of menopause have usually been discussed in relation to osteoporosis,
addressing duration of hypoestrogenic state or treatment with HRT, in relation to bone
density. More recent investigations by researchers have suggested that a potential exists for
increasing risk of breast cancer with 10 or more years of estrogen administration. In this
study, years of menopause may serve as a surrogate for years of decreasing hormone
levels. Consequently, women with more years of menopause may have a greater risk for
CVD because of extended time with loss of endogenous estrogen. Chronological age was
similar for the two subgroups addressed for years of menopause and significant HRV
values. Because research of HRV in PMW has been limited, influences of years of
menopause on HRV has not been previously delineated except as a general demographic
characteristic.
Conclusions
Research has provided extensive findings on the beneficial (as well as the
deleterious) modulatory effects of estrogen. However, limited research has examined the
effect of estrogen on cardiac autonomic function, specifically heart rate variability.
Although studies by Huikuri et al. (1996) and Rosano et al. (1997) investigated the effect
of hormone replacement therapy on HRV, the characteristics of the population represented
in those studies differed from the participants in this study across disease process,
pharmacological intervention, and use of HRT regimen.
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The aim for this research was to describe HRV in postmenopausal women before
and after six weeks of HRT in a sample of women who live in the community and seek
primary health care in a family practice clinical setting. Descriptive data confirmed expected
findings that HRV values, because of aging, were lower than laboratory norm values of
younger, healthy women, and that improved values after six weeks of HRT continued to be
lower. HRV values of PMW with and without CVD risk factors of black race, HTN, and ³
9 years of menopause, refl cted this pattern; women with risk factors generally had lower
HRV values. Values low on pre-test, generally in the frequency domains, demonstrated
improvement. HRV values improved with six weeks of HRT for PMW with selected risk
factors, particularly HTN, and principally, and consistently, for frequency domain values
of Total Hertz , Low Hertz, and High Hertz, and to a lesser extent, for time domain values
of pNN50 and rMSSD. The decreases in SDNN and SDANN were not anticipated and
merit further investigation. Because both of these time domain values reflect long-term
variability over 24 hours, differences in HRV may have been decreased by estrogen.
However time domain values of pNN50 and rMSSD, reflecting vagal influences, showed
increases, not decreases, and Total Hertz found to be highly correlated with SDNN and
also a global indicator of HRV status, showed significant (p=.01) improvement for Black
women.
The small sample size, enrollment of women with a large number of confounding
variables such as multiple CV risk factors and chronic disease, and the exploratory design
of the study limit  interpretation of these results and require a cautious review of findings.
The significant improvements in HRV for Black women following administration of HRT,
and after only six weeks, merit further research. HRV can be a powerful tool to assess
cardiac autonomic function and may be useful in clinical evaluation and management of
pathophysiological processes in older postmenopausal women, although age appropriate
referent HRV values would facilitate interpretation of findings and delineate age from
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disease effects. This study has posed many additional areas for further investigation, and
interpretations of findings are not suggestive of causality. However, this study has
provided corroborative support to the previous two studies on hormonal influences in
PMW. The extent to which HRT impacts HRV is unclear, but it is worthwhile to continue
further investigation into HRV analysis in PMW for its implications on risk stratification
and clinical management within this population. Both CVD risk factors of race and HTN
appear to be focused areas for additional inquiry with PMW using HRV to assess
cardiovascular autonomic function.
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PRE/POST-TEST HEALTH FORM
Name: SS #: Age: Date of Birth:
Years Months
Race: African-American Caucasian-American Asian-American Other
Height: Weight Blood Pressure: Pulse: Resp:
Inches lbs oz Systolic Diastolic
Current medications (including OTC drugs such as vitamins, analgesics, antacids):
Inclusion Criteria: Age: 45-60
Amenorrhea > 12 months LNMP:
Signed Consent Form
Completion of Demographic/Menopause/Health Information Form
Ability to swallow oral medication and take medication daily for 6 weeks
Willingness to repeat test in 6 weeksDate Scheduled
FSH Level > 30 mIU/ml
Estradiol Level < 30 pg/ml
Exclusion Criteria: Past history of Breast Cancer
Family history of Breast Cancer (Mother/Sister/Grandmother)
Name/Phone # of 3 relatives or friends who can be contacted in the event subject's phone number changes: 
Heart Rate Variability Analysis:Frequency Domains:Total Hertz
Low Hertz
High Hertz
Low/High Ratio
Time Domains: pNN50
SD
SDNN
SDANN
Nitric Oxide:
Pre-treatment Post-Treatment
Research Nurse/Screener Date of Test
Referral Site:
Principal Investigator Date of Analysis
Subject Phone No:
Additional Comments:
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PROTOCOL #:     07
PAGE     1 OF    1
HOLTER MONITORING:
PATIENT PREPARATION/ELECTRODE PLACEMENT
1. To minimize electrode problems, ensure good quality by checking for expiration
date. If patient is to only have Holter Monitoring , use 5 electrodes.  If Autonomic
Function is also is to be done, use 7 electrodes.
2. Apply shaving lotion and using safety razor, shave individual sites.  Shaving 
improves conductivity, holds electrode to the skin, and facilitates removal of 
electrode.
3. If skin is extremely oily, first wash designated area with soap and water.  Clean 
site with alcohol swab. Allow to air dry or dry with clean 4 X 4s.
4. Apply “dot” of liquid sandpaper, rubbing into skin with 4 X 4s, or use sandpaper
squares to further prepare each individual electrode site.
5. If patient is to only receive Holter testing, connect lead wires to each electrode
prior to applying to patient.  If patient is to have Autonomic Function testing
completed first, do not attach leads prior to electrode placement.
6. Apply electrodes.  Tape each lead wire to the chest using a stress loop to prevent
the wires from pulling directly on the electrode contact points.  The loops should
be approximately 1 to 2 inches in diameter, about 2 inches from the electrodes .
ELECTRODE PLACEMENT  
LEAD COLOR LOCATION
White Mid-Sternum-Over Manubrium     1.5 inches from clavicle
Green Right Mid-Clavicular Line               Below Costal Margin
Red Left Mid-Clavicular Line                 Below Costal Margin
Brown Right Mid-Axillary Line                   Below Costal Margin
Black Left Mid-Axillary Line                     Below Costal Margin
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PROTOCOL #:     08
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HOLTER MONITORING:  RECORDER PREPARATION
1. Use a   new   cassette tape for each patient.  A plastic bar inserted into the tape reels
signifies no previous use. Remove the bar from the tape.  Using a pencil in the
tape reel, wind the tape forward until the blank, white pre-tape is beyond the
recording site. This procedure will ensure that data is recorded from the onset of
tape recording initiation.
2. Document patient identification information on the cassette label.
Patient’s Name
Patient’s Social Security Number
Test Date
Time Test was Initiated
Recorder Identification Number: This number is written on the outer metal case.
Patient Category:  Pre-Kidney; Juvenile; Women’s Study
3. Obtain a new 9-volt alkaline battery.
4. Remove outer metal case of the recorder.  Hold the top of the recorder (the end 
which protrudes beyond the metal case) in one hand.  Slide the metal case off with
the other hand.
5. Install the battery by inserting it into the battery compartment with the positive
(+) and negative (-) terminals aligned according to the diagram inside the
compartment.  The battery should fit securely in the compartment with no space
between the bottom of the battery and the bottom of the compartment.
6. Slide the cassette release to the left.  The recording head assembly moves to the 
OUT position.
7. Place the tape in the recorder with the full reel on the supply (left) hub.  Insert 
the cassette into the recorder by placing the top edge of the cassette in first under
the retaining guides and then carefully easing the cassette down over the supply 
and take-up hubs and the cassette locator pins.
8. Prepare the patient and connect the lead wires.
9. Activate the recorder by pushing the recording head assembly   IN  (flush with the 
side of the recorder).  Visualize the take-up hub or the tape reels turning slowly.
Leave the case open while completing the additional documentation to ensure 
recorder is working properly.
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10. Complete the patient documentation on the diary:
Patient Name
Patient Social Security Number
Age Sex
Patient’s Medications
Date & Time test is initiated
Serial No:  (This number is the Holter Monitor number
Initials of individual completing test in the space for technician
11. Replace the recorder in the metal case and place inside the canvas purse.  Place
the Velcro tab across the cable/recorder site to prevent it from becoming
dislodged.  Do not push the inset button as it will erase tape.
12. Patient Instructions:
A. Maintain a 24 hour diary of activities.  Especially note:
Time went to sleep-including naps
Time awoke
Remembrance of any periods of dreaming while asleep
Exercise
Home Blood Glucose Monitoring Levels <50 or >200
Time On/Off Dialysis
Stressful Experiences
B. Do not open the canvas purse or attempt to remove the case, even when the
test is completed.
C. Wear the canvas purse by the shoulder strap or attached to a belt.
D. When the 24 hours of testing have been completed, carefully remove the 
tape over the lead wires and unsnap them from the electrodes.  Place the 
leadwires, cable, and canvas purse in the white envelope for mailing or 
return the equipment to the admissions office on first floor of Bowld 
Hospital.  Do not attempt to open the case.  Remove the electrodes and 
discard.
13. If patient wishes to mail-in equipment, provide them with a white envelope and a
Fed Ex mailing label (See example).  Identify the initials of the principle 
investigator for test on the form.  Maintain the “Sender’s Copy” in the 
Physiology Function Laboratory.  Document the monitor number and test date on 
the Sender’s Copy for future tracking purposes if necessary.
14. Document patient information into Daily Log Book and on Bulletin Board:
Name
Date of Test
Patient’s Category:  Pre-Kidney Juvenile Women’s Study
Holter Number Time Holter applied
How Holter will be returned:  Patient in town or per Federal Express.
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Consent Form
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Consent to Participate in the Study:
“Effect of PostMenopausal Hormone Replacement Therapy on
Cardiac Autonomic Function”
Please read each page carefully and place your initials at the bottom of each
page where indicated. Assistance with having the form read to you will be
provided if needed.
A. PURPOSE OF STUDY
Many research studies have shown that low estrogen production in menopause is a
risk for heart disease. These studies suggest that hormone replacement therapy (HRT)
consisting of estrogen and progesterone, taken by mouth as a pill, may reduce the chances
of developing heart disease, especially in postmenopausal women at high risk for heart
disease. This study is being done to study the effect of HRT on the cardiac autonomic
system. This system is responsible for the heart functions which occur automatically in the
body, such as regulating your heart rate and  maintaining your blood pressure. By
examining these responses, how they change during menopause, and in response to HRT,
we might be able to predict which individuals are at risk for heart disease and possibly
sudden death.
To complete this study, enrollment of fifty (50) women are necessary. If you agree
to participate, you will undergo special testing two (2) times during your six (6) weeks of
participation. You may choose to participate in either of two (2) levels of tests. To be
included, you must be 12 months past your last menstrual cycle and your blood hormone
levels must confirm that you are post-menopausal. You should have no history of breast
cancer in either yourself or your grandmother, mother, sister. You must be willing to take
two (2) pills daily by mouth for 6 weeks.
B. TESTING PROCEDURES
   QUESTIONNAIRES/HEALTH SCREENING     
The following information will be obtained prior to the tests:
1. Personal information such as your age, race, education, marital status, etc., and
health information about your physical/mental health, any medications that you are taking,
menopause experience, dietary and exercise habits, etc.
2. Basic physical screening including: height, weight, blood pressure. You also will
have 20 ml (approximately 4 teaspoons) of blood drawn to determine your hormone levels
and blood nitric oxide level. Nitric oxide helps to dilate your blood vessels and may have a
role in influencing cardiac autonomic function. To obtain an accurate result, blood samples
must be drawn prior to eating breakfast. Do not eat anything after midnight the night before
your test. If you are diabetic or require scheduled meals, bring something to eat to the
testing site.
Initials:________ Page 1 of 4
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   CARDIAC AUTONOMIC TESTS
You may choose between two types of testing. The location for obtaining testing are
different for the two tests. The second set of tests must be done at UT Bowld Research
Center at the Medical Center. Please initial to which test you are giving your consent:
1.        Holter Monitoring: This test is similar to a cardiogram, except it is done for a full 24
hours rather than in a few minutes. The monitor is similar to a tape recorder, and it
constantly records your heart beat on a tape cassette. For this test, we will put 5 patches on
your chest and tape them in place. Wires will connect the patches to the monitor. There is
no danger from these wires; no electricity is connected to the monitor. However, you will
not be able to get the patches wet or they will come off, and the test will not be able to be
used. You will wear the monitor by a strap connected to a small purse. This procedure will
be explained to you by the research assistant at the time of testing.
2.        Cardiac Autonomic Tests:  In addition to the Holter monitoring described above,
you will have further testing of cardiac autonomic function. These tests must be completed
at the Physiologic Function Lab located on 3rd floor of UT Bowld Hospital. The
procedures for these tests are:
a. Blood Vessel Test:  A small flat metal probe will be taped to the outside of
your middle finger and attached to a large machine. This probe measures the blood
flow in your finger by using infrared light waves. No needles are used in this test.
You will sit in a comfortable chair while the probe is on your finger. We will ask
you to complete several tasks during these tests. First, we will record the blood
flow in your finger while you sit quietly. Second, we will ask you to raise your arm
while we record the blood flow. Third, we will ask you to place your hand in a
basin of ice water for one minute, and we will take recordings before and after.
b. Blood Pressure Tests:  For these tests you will have a blood pressure cuff
put on your arm and attached to a machine that automatically records your blood
pressure. You will also have cardiogram patches taped to your chest to record your
heart beats. We will ask you to complete several tasks during these tests. First, we
will ask you to rest quietly on an exam bed while we record several blood
pressures. After we tell you, the bed will be tilted so that you will be placed in a
standing position. We will again check your blood pressure before returning the
bed to a lying position. Another test will be done in a comfortable chair. We will
record your heart beat and blood pressure while you are sitting quietly. Then we
will ask you to blow forcefully into a small machine for 15 seconds while we
monitor your heart beats.
Initials:________ Page 2 of 4
132
   DRUG INFORMATION
Because the purpose of this study is to investigate the effect of Hormone
Replacement Therapy (HRT) on cardiac autonomic function, you will receive HRT for 6
weeks. The medications you will be receiving are ones which are usually prescribed as
hormone replacement for menopausal women. They are    ot experimental drugs. The
medication will be provided for you in packages containing two (2) pills which you will
take every day for six (6) weeks. One pill is conjugated estrogen, known as “Premarin”,
0.625 mg; the other pill is medroxyprogesterone, know as “Provera”, 2.5 mg. The
information sheets on these medications will list potential side effects such as:  Headache,
dizziness, swelling in your legs, nausea, weight change, breast tenderness. It has been
suggested that taking estrogen   lon  term    ay increase your chance of developing breast
cancer. The drug, Provera, is necessary in women who have their uterus (womb) to
prevent the risk of endometrial cancer. It will be very important that you take    bo   drugs
during the study. The risk of any of the more serious side effects are minimal for this study
because of the short time frame (6 weeks) that you will take the drugs.
Also, because of these potential side effects, it is    strongly  suggested that you notify
your healthcare provider (physician or nurse practitioner) of your participation in this study
and that you continue your routine health or follow-up visits.
C. RISKS
The main risk in this study is exposure to potential side effects of the drugs as
previously explained. The testing by the Holter monitor should cause no discomfort other
than possible skin irritation at the site where the chest patches are taped. Mild discomfort,
bruising, or possible infection at the injection site are potential side effects of having your
blood drawn. Additionally, if you choose to participate in the complete cardiac autonomic
function tests, mild discomfort may be experienced during the ice test.
D. LEGAL RIGHTS
You are a volunteer, and you have the right to stop your participation in this study
at any time. You are not releasing any legal rights by your signature, nor are you releasing
the university or its agents from any liability or negligence. However your signature on this
consent form means that you understand that in the event of physical injury resulting from
the research procedures, the University of Tennessee, Memphis does not have funds
budgeted for compensation, either for lost wages or for medical treatment. Therefore, the
University does not provide for treatment or reimbursement for such injuries.
E. WHO TO CONTACT IF YOU HAVE QUESTIONS
If you have questions about the study  or your rights as a participant in this study,
you may contact:  Diane Pace, PhD(c), RN, CS, FNP at The University of Tennessee,
Memphis at (901) 448-1584. If you have any questions about your medical condition,
please contact your healthcare provider. If you have any questions regarding your rights as
a research subject, you can contact Dr. Clair Cox, Chairman, University of Tennessee,
Memphis, Institutional Review Board at 901-448-4824.
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F. BENEFITS OF THIS RESEARCH
Knowing how HRT effects the changes in heart beat and other cardiac autonomic
functions will provide new knowledge on how the drugs benefit women in reducing their
risk for heart disease which increases after menopause. By participating in this study you
will benefit from having a thorough examination of your autonomic function. You will also
help to define the values which might identify risks for cardiac disease.
G. CONFIDENTIALITY
All information given by you will be kept in strict confidence. Your personal
information will be coded with a subject number; no linkage will be made to your name,
nor revealed or released during the study, nor in any publication that may be completed
following the study completion. If the study results suggest a possible health problem
which might require medical attention, you will be notified and asked if you want this
information released to your provider.
H. VOLUNTARY CONSENT
I have read the description of the study entitled: “Effect of PostMenopausal
Hormone Replacement Therapy on Cardiac Autonomic Function”. I have freely
volunteered to participate in it. I have had possible side effects and adverse reactions
explained, and I have received a copy of the information sheet for the two drugs, Premarin
and Provera. It has been strongly recommended to me that I should alert my healthcare
provider of my participation in the study, and that I should continue all follow-up medical
visits and/or keep my appointment for my annual exam. I have had the opportunity to ask
questions and have received adequate answers. I understand that I may withdraw from this
study at any time.
Patient Signature : Date:
Witness Signature : Date :
Investigator Signature: Date :
Page 4 of 4
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Appendix F
Drug Documentation Calendar
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Appendix G
Normative HRV Data for Healthy Controls
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Table 15
Heart Rate Variability: Mean, Normal, Borderline, and Abnormal Values Based on the
2.3 and 5th Percentile Value for a Group of Healthy Individuals Tested Through the
Physiologic Function Laboratory1.
HRV Values Mean/SD
Values
Normal Borderline Abnormal
Frequency Domains
Total Hz 7.25 ± 0.63 ³  6.11 5.95-6.10 £  5.94
Low Hz 6.42 ± 0.66 ³  5.22 4.97-5.21 £  4.96
High Hz 5.2 ± 0.91 ³  3.45 3.29-3.44 £  3.28
Low/High Ratio
Time Domains
pNN50 11.03 ± 8.26 ³  0.6 0.4-0.5 £  0.3
SD 58 ± 15 ³  33 31-32 £  30
SDNN 134 ± 33 ³  85 79-84 £  78
SDANN 121 ± 32 ³  69 66-68 £  65
rMSSD 32.8 ± 13 ³  14 13 £  12
     Note.  Sample N=158, mean age=36.2 ± 11.2, range: 18-65 years; Men=40 (25%),
Women=118 (75%); Blacks=29 (19%); Whites=121 (77%); Other=7 (4%).
   Source.  Cashion, A. (1998). Twenty-four hour heart rate variability measures in healthy
controls. Unpublished raw data, University of Tennessee, Memphis.
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Appendix H
Data Tables:  Pre-Test Heart Rate Variability for
Postmenopausal Women Across Selected Cardiovascular Risk Factors
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Table 16
Comparisons of Pre-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Demographic Variables of Race and Age
HRV Values Demographic Variables
Race Age
Blacks Whites ³  55 yrs < 55 yrs
(n = 15) (n =  9) p1 (n = 14) (n = 10) p1
Frequency Domains
Total Hz Mean 6.18 6.29 .76 6.25 6.19 .87
SD 0.08 0.08 0.08 0.78
Low Hz Mean 5.15 5.16 .98 5.13 5.19 .87
SD 0.09 0.09 0.09 0.85
High Hz Mean 4.07 4.17 .83 4.22 3.96 .57
SD 1.09 1.09 1.13 1.00
Lo/Hi Mean 1.31 1.29 .81 1.26 1.35 .34
Ratio SD 0.19 0.27 0.22 0.22
Time Domains
pNN50 Mean 3.65 4.04 .82 4.11 3.36 .65
SD 3.96 4.06 4.00 3.97
rMSSD Mean 20.20 21.44 .73 21.57 19.40 .53
SD 8.27 8.53 7.99 8.77
SD Mean 37.93 38.11 .98 38.07 37.90 .98
SD 14.86 10.65 13.67 13.20
SDNN Mean 103.93 98.56 .65 100.79 103.50 .82
SD 32.24 16.93 22.38 34.08
SDANN Mean 95.27 89.67 .60 91.71 95.20 .74
SD 29.57 15.07 19.03 32.42
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 17
Comparisons of Pre-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Medical Variables of Diabetes Mellitus
and Hypertension
HRV Variables Medical Variables
Diabetes Mellitus Hypertension
Absent Present Absent Present
(n = 16) (n =  8) p1 (n = 13) (n = 11) p1
Frequency Domains
Total Hz Mean 6.16 6.34 .62 6.48 5.92 .09
SD 0.81 6.57 0.53 0.96
Low Hz Mean 5.07 5.33 .51 5.52 4.72 .02
SD 0.91 0.87 0.62 0.98
High Hz Mean 4.10 4.12 .97 4.28 3.91 .41
SD 1.05 1.17 0.82 1.31
Lo/Hi Mean 1.27 1.36 .38 1.32 1.28 .68
Ratio SD 0.19 0.28 0.19 0.26
Time Domains
pNN50 Mean 3.36 4.69 .44 4.40 3.09 .43
SD 3.26 5.12 4.27 3.50
rMSSD Mean 20.13 21.75 .66 22.69 18.27 .20
SD 7.40 10.10 8.35 7.72
SD Mean 37.25 39.50 .70 40.85 34.64 .26
SD 12.40 15.43 9.79 16.18
SDNN Mean 101.88 102.00 .61 104.62 98.73 .61
SD 28.45 26.37 24.80 30.70
SDANN Mean 93.63 92.25 .90 94.23 91.91 .83
SD 26.24 23.61 24.01 26.00
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 18
Comparisons of Pre-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Social Variables of Smoking Status and
Planned Exercise
HRV Variables  Social Variables
Smoking Status Planned Exercise
Absent Present Absent Present
(n = 15) (n = 9) p1 (n = 11) (n = 13) p1
Frequency Domains
Total Hz Mean 6.29 6.10 .58 6.28 6.17 .75
SD 0.83 0.77 0.75 0.86
Low Hz Mean 5.18 5.10 .53 5.28 5.05 .53
SD 0.92 0.87 0.83 0.95
High Hz Mean 4.29 3.81 .30 4.19 4.04 .73
SD 1.03 1.12 1.04 1.12
Lo/Hi Mean 1.24 1.40 .09 1.30 1.30 .99
Ratio SD 0.18 0.25 0.20 0.25
Time Domains
pNN50 Mean 4.33 2.92 .41 3.51 4.05 .75
SD 3.82 4.14 3.66 4.25
rMSSD Mean 21.87 18.67 .37 20.45 20.85 .91
SD 7.76 9.00 7.81 8.84
SD Mean 39.60 35.33 .46 37.45 38.46 .86
SD 13.68 12.63 11.82 14.71
SDNN Mean 102.00 101.78 .99 104.18 100.00 .72
SD 26.35 30.19 29.02 26.59
SDANN Mean 92.80 93.78 .93 96.27 90.54 .59
SD 24.02 27.74 27.62 23.12
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 19
Comparisons of Pre-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing in Level of Health Risk Across Medical
Variable of Body Mass Index
HRV Values
BMI < 27
Low/Moderate
Health Risk
(n = 12)
BMI ³  27
High/Very High
Health Risk
(n = 12) p1
Frequency Domains
Total Hz Mean 6.05 6.39 .31
SD 0.92 0.65
Low Hz Mean 4.93 5.38 .22
SD 1.01 0.71
High Hz Mean 3.98 4.23 .73
SD 1.19 0.96
Lo/Hi Ratio Mean 1.28 1.32
SD 0.21 0.23
Time Domains
pNN50 Mean 3.25 4.35 .50
SD 3.72 4.19
rMSSD Mean 19.50 21.83 .50
SD 8.40 8.20
SD Mean 36.17 39.83 .51
SD 14.21 12.42
SDNN Mean 97.17 106.67 .40
SD 30.36 23.99
SDANN Mean 89.17 97.19 .44
SD 27.21 22.78
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 20
Comparison of Pre-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Reproductive Variables of Age at
Menopause and Years of Menopause
HRV Variables  Reproductive Variables
Age at Menopause
Number of Years of
Menopause
³  51 yrs < 51 yrs ³  9 yrs < 9 yrs
(n = 7) (n = 17) p1 (n = 11) (n = 13) p1
Frequency Domains
Total Hz Mean 6.31 6.19 .74 5.85 6.54 .03
SD 0.84 0.80 0.76 0.70
Low Hz Mean 5.18 5.14 .93 4.68 5.56 .01
SD 0.97 0.88 0.80 0.76
High Hz Mean 4.29 4.03 .61 3.69 4.46 .06
SD 1.26 1.01 1.11 0.92
Lo/Hi Mean 1.28 1.31 .74 1.33 1.27 .54
Ratio SD 0.30 0.19 0.27 0.18
Time Domains
pNN50 Mean 3.33 3.99 .71 2.52 4.88 .14
SD 2.16 4.49 3.86 3.77
rMSSD Mean 20.14 20.88 .85 17.64 23.23 .09
SD 6.15 9.08 8.46 7.34
SD Mean 37.71 38.12 .95 31.64 43.38 .03
SD 11.84 14.04 9.67 13.67
SDNN Mean 93.00 105.59 .17 93.55 109.00 .17
SD 16.16 31.84 18.50 31.84
SDANN Mean 83.71 97.06 .25 87.27 98.15 .30
SD 14.94 27.40 16.69 29.93
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Appendix I
Data Tables:  Post-Test Heart Rate Variability for
Postmenopausal Women Across Selected Cardiovascular Risk Factors
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Table 21
Comparisons of Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Demographic Variables of Race and Age
HRV Variables  Demographic Variables
Race Age (Mean=54.9)
Blacks Whites ³  55 yrs < 55 yrs
(n = 15) (n = 9) p1 (n = 14) (n = 10) p1
Frequency Domains
Total Hz Mean 6.49 6.19 .37 6.31 6.49 .58
SD 0.64 0.98 0.89 0.63
Low Hz Mean 5.47 5.26 .54 5.28 5.54 .46
SD 0.69 1.04 0.93 0.66
High Hz Mean 4.40 3.90 .27 4.15 4.30 .74
SD 0.91 1.28 1.20 0.90
Lo/Hi Mean 1.27 1.42 .13 1.33 1.32 .90
Ratio SD 0.19 0.28 0.24 0.24
Time Domains
pNN50 Mean 4.47 4.69 .92 5.29 3.53 .42
SD 4.72 6.10 5.90 3.94
rMSSD Mean 22.13 21.33 .86 22.79 20.50 .60
SD 8.99 12.45 11.16 8.98
SD Mean 40.27 38.11 .70 39.29 39.70 .94
SD 12.03 14.47 13.30 12.59
SDNN Mean 100.40 95.00 .65 93.14 105.70 .28
SD 30.99 20.92 21.70 33.44
SDANN Mean 91.00 84.56 .58 82.86 96.60 .22
SD 30.79 18.64 20.13 33.20
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 22
Comparisons of Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Medical Variables of Diabetes Mellitus
and Hypertension
HRV Variables  Medical Variables
Diabetes Mellitus Hypertension
Absent Present Absent Present
(n =
16)
(n = 8) p1 (n = 13) (n = 11) p1
Frequency Domains
Total Hz Mean 6.42 6.31 .76 6.56 6.17 .22
SD 0.81 0.77 0.69 0.86
Low Hz Mean 5.43 5.32 .78 5.66 5.07 0.08
SD 0.88 0.75 0.66 0.91
High Hz Mean 4.27 4.12 .76 4.32 4.09 .61
SD 0.99 1.27 1.01 1.17
Lo/Hi Mean 1.30 1.38 .47 1.35 1.30 .56
Ratio SD 0.16 0.34 0.23 0.25
Time Domains
pNN50 Mean 3.66 6.35 .24 4.53 4.58 .98
SD 3.42 7.52 5.70 4.70
rMSSD Mean 21.06 23.38 .61 22.62 20.91 .69
SD 8.28 13.72 11.23 9.19
SD Mean 40.25 37.88 .68 41.46 37.09 .41
SD 12.26 14.35 12.00 13.72
SDNN Mean 100.19 94.75 .66 103.08 92.82 .37
SD 28.30 26.56 24.65 30.31
SDANN Mean 90.38 85.00 .65 93.69 82.55 .32
SD 28.31 24.25 24.05 29.34
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
147
Table 23
Comparisons of Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Social Variables of Smoking Status and
Planned Exercise
HRV Variables  Variables
Smoking Status Planned Exercise
Absent Present Absent Present
(n =
15)
(n = 9) p1 (n =
11)
(n = 13) p1
Frequency Domains
Total Hz Mean 6.52 6.15 .26 6.35 6.41 .85
SD 0.78 0.77 0.74 0.84
Low Hz Mean 5.50 5.21 .41 5.35 5.43 .81
SD 0.85 0.79 0.75 0.91
High Hz Mean 4.49 3.76 .11 4.19 4.23 .93
SD 0.93 1.18 1.14 1.05
Lo/Hi Mean 1.25 1.45 .05 1.32 1.33 .96
Ratio SD 0.16 0.29 0.24 0.24
Time Domains
pNN50 Mean 5.50 2.98 .25 4.24 4.82 .79
SD 5.49 4.36 4.53 5.79
rMSSD Mean 23.67 18.78 .26 21.73 21.93 .96
SD 9.85 10.51 10.16 10.58
SD Mean 42.00 35.22 .21 39.09 39.77 .90
SD 12.48 12.69 12.54 13.38
SDNN Mean 101.93 92.44 .42 101.91 95.38 .57
SD 27.68 27.09 32.67 22.69
SDANN Mean 91.33 84.00 .53 92.36 85.38 .53
SD 27.63 25.73 31.71 22.25
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 24
Comparisons of Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing in Level of Health Risk Across the Medical
Variable of Body Mass Index
HRV Values
BMI < 27
Low/Moderate
Health Risk
(n = 12)
BMI ³  27
High/Very High
Health Risk
(n = 12) p1
Frequency Domains
Total Hz Mean 6.32 6.44 .71
SD 0.91 0.66
Low Hz Mean 5.36 5.42 .85
SD 1.00 0.64
High Hz Mean 4.14 4.29 .75
SD 1.12 1.06
Lo/Hi Ratio Mean 1.33 1.33 .97
SD 0.17 0.29
Time Domains
pNN50 Mean 3.39 5.72 .28
SD 3.77 6.19
rMSSD Mean 20.17 23.50 .43
SD 9.21 11.18
SD Mean 39.08 39.83 .89
SD 13.91 12.04
SDNN Mean 93.08 103.67 .35
SD 24.72 29.72
SDANN Mean 82.17 95.00 .25
SD 22.34 29.87
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 25
Comparisons of Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women Differing Across Reproductive Variables of Age at
Menopause and Years of Menopause
Reproductive Variables
Age at Menopause
Number of Years of
Menopause
HRV Variables ³  51 yrs < 51 yrs ³  9 yrs < 9 yrs
(n = 7) (n = 17) p1 (n = 11) (n = 13) p1
Frequency Domains
Total Hz Mean 6.32 6.41 .85 6.13 6.60 .14
SD 0.71 0.83 0.83 0.70
Low Hz Mean 5.35 5.41 .88 5.14 5.61 .17
SD 0.70 0.89 0.89 0.72
High Hz Mean 4.13 4.25 .80 3.86 4.51 .14
SD 1.12 1.08 1.08 1.00
Lo/Hi Mean 1.35 1.32 .72 1.38 1.28 .31
Ratio SD 0.26 0.23 0.26 0.21
Time Domains
pNN50 Mean 4.27 4.67 .87 3.62 5.35 .43
SD 3.73 5.73 5.60 4.82
rMSSD Mean 21.57 21.94 .94 19.27 24.00 .27
SD 8.32 11.06 11.12 9.16
SD Mean 40.14 39.18 .87 34.45 43.69 .08
SD 12.23 13.29 11.82 12.32
SDNN Mean 88.86 102.29 .28 90.27 105.23 .19
SD 21.77 28.91 18.29 32.18
SDANN Mean 77.14 93.29 .18 82.36 93.85 .30
SD 18.36 28.47 19.00 31.48
1 t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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        Appendix J
Data Tables:  Differences Between Pre- and Post-Test Heart Rate Variability for
Postmenopausal Women Across Selected Cardiovascular Risk Factors
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Table 26
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability in
Postmenopausal Women Across and Within Demographic Variable of Age
HRV Variables  Demographic Variables
Age ³  55 years (n = 14) Age < 55 years (n = 10)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.25 6.31 .68 6.19 6.49 .06
SD 0.08 0.89 0.78 0.63
Low Hz Mean 5.13 5.28 .39 5.19 5.54 .05
SD 0.09 0.93 0.85 0.66
High Hz Mean 4.22 4.15 ¯ .72 3.96 4.30 .07
SD 1.13 1.20 1.00 0.90
Lo/Hi Mean 1.26 1.33 ­ .14 1.35 1.32 ¯ .39
Ratio SD 0.22 0.24 0.22 0.24
Time Domains
pNN50 Mean 4.11 5.29 .11 3.36 3.53 .71
SD 4.00 5.90 3.97 3.94
rMSSD Mean 21.57 22.79 .38 19.40 20.50 .30
SD 7.99 11.16 8.77 8.98
SD Mean 38.07 39.29 .53 37.90 39.70 .28
SD 13.67 13.30 13.20 12.59
SDNN Mean 100.79 93.14 ¯ .06 103.50 105.70 .62
SD 22.38 21.70 34.08 33.44
SDANN Mean 91.71 82.86 ¯ .05 95.20 96.60 .79
SD 19.03 20.13 32.42 33.20
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 27
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability in
Postmenopausal Women By Absence/Presence of Diabetes Mellitus
HRV Variables  Medical Variables
Diabetes-Absent (n = 16) Diabetes-Present (n = 8)
Pre-TestPost-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.16 6.42 .03 6.34 6.31 .89
SD 0.81 0.81 6.57 0.77
Low Hz Mean 5.07 5.43 .02 5.33 5.32 .98
SD 0.91 0.88 0.87 0.75
High Hz Mean 4.10 4.27 .32 4.12 4.12 1.00
SD 1.05 0.99 1.17 1.27
Lo/Hi Mean 1.27 1.30 ­ <.001 1.36 1.38 ­ .66
Ratio SD 0.19 0.16 0.28 0.34
Time Domains
pNN50 Mean 3.36 3.66 .32 4.69 6.35 .20
SD 3.26 3.42 5.12 7.52
rMSSD Mean 20.13 21.06 .26 21.75 23.38 .48
SD 7.40 8.28 10.10 13.72
SD Mean 37.25 40.25 .02 39.50 37.88 ¯ .57
SD 12.40 12.26 15.43 14.35
SDNN Mean 101.88 100.19 ¯ .60 102.00 94.75 ¯ .27
SD 28.45 28.30 26.37 26.56
SDANN Mean 93.63 90.38 ¯ .40 92.25 85.00 ¯ .30
SD 26.24 28.31 23.61 24.25
1Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 28
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability for
Postmenopausal Women By Smoking Status
HRV Variables  Social Variables
Non-Smoker (n = 15) Smoker (n = 9)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.29 6.52 .05 6.10 6.15 .83
SD 0.83 0.78 0.77 0.77
Low Hz Mean 5.18 5.50 .03 5.10 5.21 .66
SD 0.92 0.85 0.87 0.79
High Hz Mean 4.29 4.49 .21 3.81 3.76 ¯ .84
SD 1.03 0.93 1.12 1.18
Lo/Hi Mean 1.24 1.25 ­ .77 1.40 1.45 ­ .22
Ratio SD 0.18 0.16 0.25 0.29
Time Domains
pNN50 Mean 4.33 5.50 .10 2.92 2.98 .88
SD 3.82 5.49 4.14 4.36
rMSSD Mean 21.87 23.67 .12 18.67 18.78 .94
SD 7.76 9.85 9.00 10.51
SD Mean 39.60 42.00 .08 35.33 35.22 .97
SD 13.68 12.48 12.63 12.69
SDNN Mean 102.00 101.93 ¯ .98 101.78 92.44 ¯ .09
SD 26.35 27.68 30.19 27.09
SDANN Mean 92.80 91.33 ¯ .70 93.78 84.00 ¯ .13
SD 24.02 27.63 27.74 25.73
1Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 29
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability
for Postmenopausal Women By Exercise Status
HRV Variables  Social Variables
Non-Exercisers (n = 11) Exercisers (n = 13)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency
Domains
Total Hz Mean 6.28 6.35 .70 6.17 6.41 .07
SD 0.75 0.74 0.86 0.84
Low Hz Mean 5.28 5.35 .75 5.05 5.43 .02
SD 0.83 0.75 0.95 0.91
High Hz Mean 4.19 4.19 1.00 4.04 4.23 .28
SD 1.04 1.14 1.12 1.05
Lo/Hi Mean 1.30 1.32 ­ .48 1.30 1.33 ­ .57
Ratio SD 0.20 0.24 0.25 0.24
Time Domains
pNN50 Mean 3.51 4.24 .31 4.05 4.82 .22
SD 3.66 4.53 4.25 5.79
rMSSD Mean 20.45 21.73 .42 20.85 21.93 .32
SD 7.81 10.16 8.84 10.58
SD Mean 37.45 39.09 .45 38.46 39.77 .42
SD 11.82 12.54 14.71 13.38
SDNN Mean 104.18 101.91 ¯ .64 100.00 95.38 ¯ .24
SD 29.02 32.67 26.59 22.69
SDANN Mean 96.27 92.36 ¯ .42 90.54 85.38 ¯ .29
SD 27.62 31.71 23.12 22.25
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 30
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability
for Postmenopausal Women Across and Within the Medical Variable of Body
Mass Index
HRV Variables  Body Mass Index
BMI < 27 (n = 12) BMI ³  27 (n = 12)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.05 6.32 .07 6.39 6.44 .75
SD 0.92 0.91 0.65 0.66
Low Hz Mean 4.93 5.36 .02 5.38 5.42 .80
SD 1.01 1.00 0.71 0.64
High Hz Mean 3.98 4.14 .45 4.23 4.29 .75
SD 1.19 1.12 0.96 1.06
Lo/Hi Mean 1.28 1.33 ­ .43 1.32 1.33 ­ .76
Ratio SD 0.21 0.17 0.23 0.29
Time Domains
pNN50 Mean 3.25 3.39 .69 4.35 5.72 .11
SD 3.72 3.77 4.19 6.19
rMSSD Mean 19.50 20.17 .07 21.83 23.50 .27
SD 8.40 9.21 8.20 11.18
SD Mean 36.17 39.08 .53 39.83 39.83 1.00
SD 14.21 13.91 12.42 12.04
SDNN Mean 97.17 93.08 ¯ .04 106.67 103.67 ¯ .56
SD 30.36 24.72 23.99 29.72
SDANN Mean 89.17 82.17 ¯ .23 97.19 95.00 ¯ .70
SD 27.21 22.34 22.78 29.87
1Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 31
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability
for Postmenopausal Women By Age at Menopause
HRV Variables  Age at Menopause
³  51 years (n = 7) < 51 years (n = 17)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.31 6.32 .96 6.19 6.41 .05
SD 0.84 0.71 0.80 0.83
Low Hz Mean 5.18 5.35 .62 5.14 5.41 .03
SD 0.97 0.70 0.88 0.89
High Hz Mean 4.29 4.13 ¯ .62 4.03 4.25 .11
SD 1.26 1.12 1.01 1.08
Lo/Hi Mean 1.28 1.35 ­ .33 1.31 1.32 ­ .85
 Ratio SD 0.30 0.26 0.19 0.23
Time Domains
pNN50 Mean 3.33 4.27 .41 3.99 4.67 .17
SD 2.16 3.73 4.49 5.73
rMSSD Mean 20.14 21.57 .53 20.88 21.94 .26
SD 6.15 8.32 9.08 11.06
SD Mean 37.71 40.14 .46 38.12 39.18 .42
SD 11.84 12.23 14.04 13.29
SDNN Mean 93.00 88.86 ¯ .48 105.59 102.29 ¯ .36
SD 16.16 21.77 31.84 28.91
SDANN Mean 83.71 77.14 ¯ .27 97.06 93.29 ¯ .37
SD 14.94 18.36 27.40 28.47
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Differences Between Pre- and Post-Test HRV in Black Women
Because of the significant differences in mean values of the frequency domains
between pre- and post-tests in the Black women (see Table 11), further analyses were done
on specific variables within that population. Tables 32 through 35 summarize the changes
found using paired t-tests to examine differences between the means across the variables of
presence/absence of hypertension, smoking status, exercise status, and years of
menopause.
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Table 32
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability for
Black Postmenopausal Women Across and Between the Absence/Presence of
Hypertension
HRV Variables  Medical Variables
Hypertension-Absent (n = 6)Hypertension-Present (n =9)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.48 6.78 .12 5.98 6.31 .08
SD 0.72 0.68 0.90 0.58
Low Hz Mean 5.49 5.82 .12 4.92 5.24 .14
SD 0.81 0.75 0.91 0.57
High Hz Mean 4.34 4.58 .21 3.89 4.29 .04
SD 0.97 0.93 1.17 0.94
Lo/Hi Mean 1.29 1.29 .91 1.32 1.26 ¯ .09
Ratio SD 0.13 0.12 0.23 0.23
Time Domains
pNN50 Mean 4.33 3.75 ¯ .33 3.20 4.96 .03
SD 4.45 4.66 3.82 4.98
rMSSD Mean 22.83 22.67 ¯ .92 18.44 21.78 .006
SD 8.70 9.83 7.99 8.98
SD Mean 41.67 43.67 039 35.44 38.00 .23
SD 12.77 11.36 16.34 12.57
SDNN Mean 109.83 107.67 ¯ .69 100.00 95.56 ¯ .44
SD 32.42 29.26 33.45 32.86
SDANN Mean 99.50 99.33 ¯ .98 92.44 85.44 ¯ .23
SD 31.15 29.71 30.03 31.95
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 33
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability
for Black Postmenopausal Women Across and Between Smoking Status
HRV Variables  Medical Variables
Non-Smoker (n = 10) Smoker (n =5)
Pre-TestPost-Test p1 Pre-TestPost-Test p1
Frequency Domains
Total Hz Mean 6.29 6.58 .09 5.98 6.33 .11
SD 0.77 0.48 1.03 0.94
Low Hz Mean 5.27 5.57 .12 4.92 5.29 .18
SD 0.79 0.48 1.14 1.04
High Hz Mean 4.23 4.58 .06 3.75 4.05 .11
SD 0.93 0.57 1.41 1.40
Lo/Hi Mean 1.27 1.23 ¯ .20 1.38 1.36 ¯ .19
Ratio SD 0.15 0.12 0.26 0.28
Time Domains
pNN50 Mean 3.51 4.59 .22 3.94 4.24 .13
SD 3.29 4.58 5.53 5.54
rMSSD Mean 20.40 22.10 .25 19.80 22.20 .009
SD 6.54 7.28 11.97 12.79
SD Mean 39.10 40.90 .35 35.60 39.00 .22
SD 14.26 11.29 17.47 14.71
SDNN Mean 102.10 102.80 .88 107.60 95.60 ¯ .08
SD 31.61 31.98 36.95 31.89
SDANN Mean 92.40 93.90 .77 101.00 85.20 ¯ .02
SD 29.61 32.49 32.04 29.66
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 34
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability
for Black Postmenopausal Women Across and Between Exercise Status
HRV Variables  Medical Variables
Non-Exerciser (n = 8) Exerciser (n =7)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 6.22 6.47 .11 6.14 6.52 .09
SD 0.87 0.73 0.88 0.58
Low Hz Mean 5.18 5.40 .23 5.12 5.55 .09
SD 0.95 0.81 0.89 0.58
High Hz Mean 4.11 4.34 .05 4.03 4.48 .09
SD 1.21 1.18 1.02 0.55
Lo/Hi Mean 1.32 1.29 ¯ .22 1.30 1.25 ¯ .26
Ratio SD 0.23 0.25 0.16 0.09
Time Domains
pNN50 Mean 3.76 4.98 .19 3.53 3.90 .62
SD 4.23 4.94 3.97 4.78
rMSSD Mean 20.38 23.50 .02 20.00 20.57 .69
SD 9.15 10.62 7.87 7.18
SD Mean 37.63 41.25 .04 38.29 39.14 .75
SD 13.53 11.74 17.36 13.18
SDNN Mean 110.75 108.75 ¯ .74 96.14 90.86 ¯ .33
SD 31.27 33.57 33.95 26.95
SDANN Mean 103.63 98.88 ¯ .46 85.71 82.00 ¯ .57
SD 28.60 33.41 29.79 27.07
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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Table 35
Differences Between Pre- and Post-Test Mean Values for Heart Rate Variability
for Black Postmenopausal Women Across and Between Years of Menopause
HRV Variables  Years of Menopause
³  9 years (n = 5) < 9 years (n = 10)
Pre-Test Post-Test p1 Pre-Test Post-Test p1
Frequency Domains
Total Hz Mean 5.59 6.18 .03 6.48 6.65 .20
SD 0.61 0.49 0.80 0.67
Low Hz Mean 4.52 5.19 .03 5.46 5.62 .33
SD 0.68 0.55 0.84 0.73
High Hz Mean 3.35 4.02 .05 4.43 4.60 .12
SD 0.81 0.55 1.05 1.02
Lo/Hi Mean 1.38 1.29 ¯ .16 1.27 1.26 ¯ .53
Ratio SD 0.17 0.13 0.20 0.22
Time Domains
pNN50 Mean 1.02 1.90 .05 4.97 5.76 .36
SD 1.06 1.46 4.26 5.31
rMSSD Mean 14.40 16.80 .0006 23.10 24.80 .25
SD 4.28 4.27 8.39 9.70
SD Mean 27.60 32.40 .03 43.10 44.20 .58
SD 5.86 8.56 15.47 11.87
SDNN Mean 86.80 83.60 ¯ .60 112.50 108.80 ¯ .49
SD 18.38 19.74 34.96 32.94
SDANN Mean 81.60 77.80 ¯ .67 102.10 97.60 ¯ .39
SD 18.85 23.40 32.36 32.96
1 Paired t-Test: Significant at p = £  .05 Trend at p = £  .10 > .05
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